Isis 3521 and G3139 are, respectively, a 20 -mer and an 18 -mer phosphorothioate oligonucleotide targeted to the PKC -and bcl -2 mRNAs. Treatment of T24 bladder and PC3 prostate carcinoma cells with full -length and 3 0 truncation mutants of Isis 3521 causes downregulation of PKCprotein and mRNA. However, at the level of a 15 mer and shorter, downregulation of mRNA expression is no longer observed. Further, no diminution in cellular viability, as measured by MTT assay, in response to increasing concentrations of paclitaxel, can be observed for these shorter oligomers. These observations not only indicate that PKC -protein expression can be downregulated by both RNase -H dependent and independent mechanisms, but that downregulation of PKC -by itself is not sufficient to ''chemosensitize'' cells. G3139, which downregulates bcl -2 protein and mRNA expression, also downregulates PKC -protein and mRNA expression, but not that of PKC -I, or . However, the downregulation of PKC -and bcl -2 are not linked. When the carrier Eufectin 5 is employed, only bcl -2 is downregulated in both T24 and PC3 cells at 50 nM oligonucleotide concentration. At 100 nM, both bcl -2 and PKC -expression are downregulated, and only at this concentration can ''chemosensitization'' to paclitaxel and carboplatin be observed. In contrast, the downregulation of bcl -2 appears to be linked with that of RelA ( p65 ). However, this too is also not sufficient for chemosensitization, even though it leads to the loss of expression of genes under the putative control of NF -B, and to detachment of the cells from plastic surfaces. Nevertheless, a possible requirement of bcl -2 inhibition for G3139 -induced chemosensitivity may be seen in DU145 cells in which bcl -2 protein expression has been stably, > 90% downregulated by an antisense RNA strategy. Subsequent treatment of these cells with G3139 does not produce any chemosensitization to either paclitaxel or mitoxantrone. These results underscore the complexity of the intracellular requirements for the initiation of chemosensitization to anti -neoplastic agents.
and clinical approaches. The 4625 antisense oligonucleotide targets a region of high homology in the bcl -2 / bcl -xL mRNAs and thereby simultaneously downregulates Bcl -2 and Bcl -xL. 4625 is a phosporothioate 20 -mer second -generation ''wingmer'' high -affinity oligonucleotide. We investigated the anti -tumor potential of the 4625 oligonucleotide in combination with chemotherapeutic drugs in vitro and in vivo.
Methods: 4625 -mediated inhibition on Bcl -2 and Bcl -xL protein expression was assessed by immuno -blotting. Growth inhibition and induction of cell death were determined by MTT Assay and FACS analysis on different lung, breast and colorectal tumor cell lines. For in vivo experiments mice were treated systemically with 4625 alone or in combination with chemotherapy. Paclitaxel and 5 -FU were chosen as standard therapy for breast and colorectal cancer. The 4626 mismatch oligonucleotide was used as a negative control.
Results: 4625 downregulates Bcl -2 and Bcl -xL expression in cancer cell lines of diverse histological origins. It further leads to proliferation inhibition at concentrations ranging from 75 to 600 nM and cell death induction in a dose -dependent manner. The anti -tumor activity of the 4625 oligonucleotide in vitro works independent from cellular Bcl -2 / Bcl -xL expression patterns. 4625 further synergistically interacts with various chemotherapeutic agents. The ip. application of 4625 with or without Paclitaxel / 5 -FU led to a significant growth inhibition of established human carcinoma xenografts in nude mice.
Discussion: Several antisense oligonucleotides are currently undergoing clinical studies for a targeted treatment of solid tumors. A bispecific antisense could reach better anti -tumor effects since the survival of different cancer cells depends more on either bcl -2 or bcl -xL expression. Furthermore Bcl -2 and Bcl -xL are often heterogeneously expressed in solid tumor tissues and most lung carcinomas do overexpress both proteins. Our data suggest that state -of -the -art antisense technology offers a potent approach to inhibit the expression of the two major anti -apoptotic proteins Bcl -2 and Bcl -xL with one single oligonucleotide. The broad activity of 4625 against different tumors could make more patients benefit from a treatment with this antisense oligonucleotide.
upon -Tyne, UK; 3 Institute of Pathology, Charité, Humboldt University Berlin, Germany. OBJECTIVE: Telomerase is a promising target for human cancer gene therapy. Its inhibition allows telomere shortening to occur in cancer cells, which in turn is thought to trigger delayed senescence and / or apoptosis. We tested whether telomerase inhibition might have additional, immediate effects on tumor cell growth.
METHODS: Four ovarian cancer cell lines with differing telomere lengths were transduced with an adenovirus expressing a ribozyme directed against the T motif of the catalytic subunit of human telomerase, hTERT. hTERT mRNA was measured by RT-PCR. Telomerase activity was measured by the semiquantitative TRAP -Assay. The percentage of apoptotic cells was estimated by flow cytometry.
RESULTS: Three days after transduction, telomerase activity was significantly reduced and massive cell loss was induced in mass cultures from all four ovarian cancer cell lines tested, while transduction of telomerase -negative human fibroblasts did not attenuate their growth. The kinetics of induction of cell death in cancer cells was not significantly dependent on telomere length, and telomeres did not shorten measurably before the onset of apoptosis.
CONCLUSION: The data suggest the existence of a ''fast track'' mechanism by which diminution of telomerase can interfere with cancer cell growth and induce cell death, presumably by apoptosis. This phenomenon might be a consequence of the telomere capping function provided by telomerase in tumor cells. Uncapping of telomeres by ribozyme -mediated inhibition of telomerase bears therapeutic potential for ovarian cancer.
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Novel intracellular single -stranded DNA expression system: Production of c -raf RNA -cleaving DNA enzyme Antisense therapy involves the use of antisense oligodeoxyribonucleotides ( ODNs ) for altering targeted gene function. However, the instability of antisense ODNs and the low efficiency of cell delivery have limited the efficacy of antisense therapeutic approaches. To circumvent these difficulties, we developed an expression system that can produce intracellularly single -stranded DNA ( ssDNA ) such as antisense ODNs. This new generation expression system is an improvement of our first -generation two -vector expression system ( Chen et al., Antisense and Nucleic Acid Drug Development, 10: 415 -422, 2000 ) . To test this novel expression system, we chose to express a single -stranded ''10 -23'' DNA enzyme targeting c -raf mRNA in human lung carcinoma A549 cell line. After introduction into cells by transient transfection, DNA enzymes produced by this expression vector, significantly suppressed the expression of c -raf mRNA. Furthermore, the expressed c -raf DNA enzymes induced cell apoptosis as indicated by genomic DNA fragmentation assay. Our study demonstrates the feasibility of using this novel ssDNA expression system to produce intracellularly a sequence of interest that alters gene function, as well as the broad applicability of this expression technology for antisense, triplex, or DNA enzyme therapies.
A recombinant adenovirus containing a modified retinoblastoma ( RB ) gene, which utilizes the second start codon of the RB gene and encodes for a 94 -kDa protein ( AdpRB94 ), has been reported to be a more potent tumor suppressor and cytotoxic agent than an adenovirus encoding the wild -type RB protein ( AdpRB110 ). The anti -tumor activity of AdRB94 has been demonstrated in numerous cancer cell lines irrespective of tumor type and status of RB or other genetic factors. AdRB94 also has been shown not to be cytotoxic or growth inhibitory to normal human cells, including urothelial cells. Therefore, AdRB94 is expected to have a high therapeutic index and broad -spectrum tumor suppressor activity. Recent results utilizing an adenoviral -mediated RB94 expression system under tetracycline control strongly suggests that there is a unique mechanism of RB94 induced tumor cell death. This specific mechanism and our hypothesis why AdRB94 kills tumor cells but not normal cells will be discussed in detail. A Phase I clinical trial for superficial bladder cancer using intravesical AdRB94 is now being planned. To enhance adenovirus -mediated gene transfer and expression in the bladder, the reagent Syn3 will be used. Intravesical administration of Syn3 has been shown to markedly increase adenoviral -mediated transgene expression without significant toxicity in both large and small animal models. Preclinical results with Syn3 will be presented together with a model to explain why AdRB94 can be cytotoxic to genetically altered, normal appearing urothelium.
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Novel combinatorial gene -therapy for pancreatic cancer Pancreatic cancer is an extremely aggressive neoplasm whose incidence equals its death rate. Although extensively investigated, key genetic changes mediating pancreatic cancer development and therapies for diminishing the morbidity associated with this disease remain unsolved. Through subtraction hybridization, a gene associated with induction of irreversible growth arrest, cancer reversion and terminal differentiation in human melanoma cells, melanoma differentiation associated gene -7 ( mda -7 ) has been identified. Ectopic expression of mda -7 using a replication incompetent adenovirus, Ad.mda -7, induces growth suppression and programmed cell death ( apoptosis ) in a wide spectrum of human cancers manifesting diverse genetic defects, without exerting deleterious effects in normal human epithelial or fibroblast cells. In spite of the apparently ubiquitous antitumor effects of mda -7, pancreatic carcinoma cells are remarkably refractory to Ad.mda -7 induced growth suppression and apoptosis. Pancreatic carcinoma cells contain multiple genetic alterations, including activation of the K -ras oncogene ( 85% to 95% ) and inactivation of the p16 / RB1 ( > 90% ), p53 ( 75% ) and DPC4 ( 55% ) tumor suppressor genes. These findings highlight the complexity of this cancer and may provide a partial explanation for its aggressiveness and inherent resistance to conventional therapies, including radiation and chemotherapy, as well as to mda -7. Remarkably, although ineffective when used individually, infection with Ad.mda -7 plus treatment with antisense ( AS ) phorphorothioate oligonucleotides targeting the K -ras oncogene dramatically suppresses growth and decreases cell viability by promoting apoptosis. In mutant K -ras pancreatic carcinoma cells apoptosis correlates with expression and an increase, respectively, in MDA -7 and BAX proteins and increases in the ratio of BAX to Bcl -2 proteins. Moreover, transfection of mutant K -ras pancreatic carcinoma cells with an AS K -ras expression vector and infection with Ad.mda -7 inhibits colony formation in vitro and tumorigenesis in vivo in nude mice. These intriguing observations demonstrate that a combinatorial approach, consisting of a cancer -specific apoptosis -inducing gene and an oncogene inactivation strategy, may provide the foundation for developing an effective therapy for pancreatic cancer.
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A Phase I dose -escalation study of Ad -mda7 (INGN 241 ) The mda -7 gene is a novel tumor suppressor gene. The objective of this study is to determine the safety and pharmacokinetics of a single intratumoral injection of INGN 241 ( Ad -mda7 ). Patients with advanced carcinoma who had a surgically resectable lesion received a single injection of INGN 241 at doses ranging from 2Â10 10 to 2Â10 12 viral particles ( vp ). Twenty -four hours after injection, the lesions were surgically removed, serially sectioned, and analyzed for vector distribution, MDA -7 protein expression, and apoptosis induction.
DNA PCR of the injected lesion exhibited a dose -dependent response in the number of Ad -mda7 vector copies / g DNA ranging from 7Â10 6 at the 2Â10 10 vp ( low dose ) up to 4Â10 8 at 2Â10 12 vp ( high dose ). DNA PCR also revealed that the highest number of Ad -mda7 vector copies was located at the center of the injected lesion. Both MDA -7 protein and vector DNA could be detected in sections up to 1 cm from the point of injection. RT-PCR and IHC analyses showed that both vector RNA and MDA -7 protein levels had a similar correlation with both dose and distance from the injection site. Strong MDA -7 staining was found in all injected lesions, whereas noninjected lesion controls were negative. Low dose INGN 241 injection resulted in up to 20% MDA -7 positive cells at the center of the tumor; high dose injection resulted in up to 80% of MDA -7 positive cells. Apoptotic TUNEL staining was most intense in the center of the lesions, with up to 70% of cells being positive; sections in the periphery of the tumor also showed a markedly stronger TUNEL reaction as compared with uninjected lesions. INGN 241 appears to be safe with mild toxicities observed, consistent with those seen previously with Ad5 -CMVp53. This is the first study to evaluate distribution of INGN 241 within tumors and suggests that INGN 241 can induce apoptosis in a large percentage of tumor volume following intratumoral administration.
Cancer Gene Therapy, Vol 8, Suppl Adenovirus -mediated over expression of the melanoma differentiation associated gene -7 ( Ad -mda7 ) in vitro results in selective suppression of lung tumor proliferation. However, the ability of Ad -mda7 to suppress lung tumors in vivo has not been previously demonstrated. In the present study we investigated the effects of Ad -mda7 treatment on growth of xenograft human non -small cell lung carcinoma tumors ( NSCLC ) in vivo. Ad -mda7 treatment of p53 wild type A549 and p53 null H1299 subcutaneous lung tumor xenografts resulted in significant ( p = 0.01 ) suppression of tumor growth compared to those treated with control vector expressing the luciferase gene ( Ad -luc ). Immunohistochemical analysis of tumor tissues demonstrated tumor cells expressing the MDA -7 protein underwent apoptotic cell death. Furthermore, analysis for microvessel density ( MVD ) demonstrated significant decrease in CD31 / PECAM expression in tumors treated with Ad -mda7 that correlated with decreased VEGF expression. Additional evidence demonstrating the anti -angiogenic activity of Ad -mda7 was its ability to inhibit human umbilical vein endothelial cell differentiation ( tube formation ) in vitro. These results indicate that Admda7 has both anti -tumor and anti -angiogenic activity, and is a potential gene therapeutic for lung cancer.
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PEDF as a novel anti -angiogenic factor for cancer gene therapy Solid tumors depend on angiogenesis for their growth. The magnitude of tumor vascularization correlates with the extent of the disease and the increased potential to form metastases. Inhibitors of angiogenesis are thus being investigated as valuable approaches to anti -cancer therapy. In this study, we show that Pigment Epithelium -Derived Factor ( PEDF ), a potent inhibitor of angiogenesis found naturally in the normal eye, inhibits tumor growth by blocking blood vessel formation in mouse models. Systemic PEDF expression was obtained using a novel strategy of non -viral muscle gene delivery coupled with electroporation. Prolonged PEDF protein expression was responsible for the reduction of tumor burden across several models including mice that are transgenic for the activated rat Her2 / neu oncogene, and thus spontaneously develop mammary adenocarcinomas. Evidence for anti -angiogenesis was demonstrated by a decrease of tumor blood vessels, quantified by CD31 -staining, in mice treated with PEDF gene in comparison to untreated mice or mice treated with an irrelevant gene. Finally, we show that PEDF cancer gene therapy augments the anti -tumor effect of chemotherapeutic agents by significantly increasing time to progressive disease, by inducing sustained regression of established tumors and by improving overall survival.
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Anti -angiogenic suppression of tumor growth in vivo by adenoviral and lentiviral gene transfer of thrombospondin -1 and endostatin Gene therapy strategies for in vivo production of anti -angiogenic factors offer the potential to achieve more efficient inhibition of tumor growth compared to peptide therapy via chronic systemic infusion. We have developed both adenovirus and lentivirus vectors encoding the antiangiogenic factors thrombospondin -1 ( TSP -1 ) and endostatin, and have confirmed their anti -proliferative effects on endothelial cells in culture. To further examine their tumor inhibitory activities in vivo, we have tested these vectors in a number of animal models of pre -established cancer.
The lentivirus vector Sin -End, which expresses a secreted form of murine endostatin linked to GFP marker gene expression via an internal ribosome entry site, was tested in a pre -established NMU rat mammary tumor model. In contrast to control vectors expressing GFP alone ( Sin -GFP ), a single intratumoral injection of 1.2Â10 7 transducing units ( TU ) of Sin -End resulted in effective suppression of tumor growth accompanied by ulcerative necrosis of the tumor mass. Moreover, untreated contralateral tumors in the same mice also showed growth inhibition associated with increased levels of endostatin in the general circulation.
Adenovirus vectors expressing human TSP -1 and GFP ( Ad -TSP -GFP ), or the corresponding control vector Ad -GFP, were also applied in vivo to a pre -established subcutaneous tumor model using Lewis lung carcinoma cells. The treatment group, injected with 5.0Â10
8 TU of Ad -TSP -GFP twice intratumorally, showed significant inhibition of tumor growth compared to the Ad -GFP -injected control group.
These results demonstrate the potential of anti -angiogenic strategies employing virus vector -mediated gene transfer to achieve effective inhibition of solid tumors and distant site metastases in vivo.
This work was supported in part by American Cancer Society grant RPG -99 -355 -01 -MGO, and fellowships ( TS, CKT ) from the Susan G. Komen Breast Cancer Foundation. Loss of expression of the Fhit protein is a common finding in many cancers of epithelial origin including lung, bladder, head and neck, breast and cervical carcinomas, suggesting a possible tumor suppressor role for this protein. In order to investigate the effect of restoration of Fhit expression in lung tumors we have constructed an adenoviral vector containing FHIT cDNA ( Ad -Fhit ) and used it to transduce seven lung cancer cell lines lacking endogenous protein expression and representing all the different histological subtypes of non small cell lung cancer ( NSCLC ). Transfer of the FHIT gene resulted in increased sensitivity to apoptosis in all the lines tested as measured by the TUNEL assay quantified using flow cytometry. The number of cells showing evidence of apoptosis ranged from 10% to 53% depending on the cell line and the conditions used with maximum effect observed on the H460 large cell carcinoma. Fhit -induced apoptosis was always associated with evidence of activation of caspase -8 and was particularly elevated when other exogenous apoptotic stimuli were added to the transduced cells ( e.g., starvation ) indicating that Fhit may increase sensitivity to apoptosis in some cell types. Consistently with this hypothesis H460 cells stably transfected with a Fhit expressing plasmid were highly susceptible to Fas -induced apoptosis when compared to the parental cell line. Furthermore Ad -Fhit transduced cells also showed a marked reduction in their tumorigenic potential: 12 / 12 nude mice inoculated subcutaneously with 1Â10 To test this hypothesis, we developed antisense oligonucleotides that efficiently block Egr -1 expression. They were designed based on the following criteria.
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-Sequences are significantly different from Egr isoforms, namely Egr -2, -3, and -4.
-They are identical in murine and human Egr -1, which will allow direct translation from murine to human applications. -A search was conducted using NIH / BLAST to discard sequences shared with unrelated genes. -Oligonucleotides are 20 mer -long phosphorothioate analogs, have no CpG inclusions, no runs of G and no palindrome sequences.
We obtained two antisense oligonucleotides that efficiently inhibited Egr -1 protein expression as shown by Western blot analysis. The inhibition was dose -dependent with an EC 50 of 0.1 M and maximum efficiency of $90% inhibition between 0.2 and 0.4 M. The antisense oligonucleotides did not alter expression of Egr -2 but were reactive in both human and murine cells Inhibition was observed for up to 56 hours, which allows longterm in vitro studies such as cell growth determinations and phenotypic observations. The TRAMP -C cell lines were used as a murine model of prostate cancer cells. It was observed that Egr -1 expression levels are higher in C2 > C3 > C1. Antisense oligonucleotides inhibited Egr -1 expression by more than 80% in the three cell lines. It is predicted that blocking the expression of Egr -1 in prostate cancer cells will inhibit the effects of Egr -1 on gene expression and decrease prostate cells proliferation.
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Observations on bringing gene therapy from limited access Phase I/II trials to the level of a multinational Phase III trial University of Oklahoma, Oklahoma City, OK. Based upon favorable findings from the completion of an extended Phase I / II trial of p53 gene replacement for the treatment of recurrent ovarian cancer, an international, multi -institutional, randomized, phase III trial of intraperitoneal ( IP ) rAd p53 ( SCH 58500 ) for the primary treatment of advanced ovarian cancer was initiated in January, 1999.
Key requirements for enrollment included FIGO stage III ovarian or primary peritoneal carcinoma, cytoreduced to no more than 2 -cm residual disease, adequate performance status, and a tumor p53 mutation. Informed consent was obtained prior to any non -standardized testing. Patients were stratified on the basis of: 1 ) residual disease ( from 0.5 to 1 cm; from 1 cm to 2 cm ) and preoperative CA125 ( elevated: normal ). All patients were planned to receive six cycles of conventional carboplatin / paclitaxel chemotherapy. The first cycle of chemotherapy occurred before randomization and required a minimum of platinum / taxane dosing. P53 sequence mutation / deletion was required and randomization occurred within 35 days of day 1 of cycle 1. Those in Treatment Arm A continued with conventional chemotherapy ( carboplatin / taxol ) while those in Treatment Arm B received IP SCH 58500 ( 7.5Â10 13 particles / dose ) daily times 5 for cycles 2 -6 plus conventional chemotherapy.
Potential treating institutions included 86 US centers and 36 international sites. A total of 394 tissue samples were submitted for p53 sequencing between 3 / 1999 and 3 / 2001. P53 mutations were sequenced from 77.1% of the submitted samples. The study was terminated when an interim analysis on the primary endpoint ( time to progression ) in 114 patients strongly suggested that the overall study would not reach its endpoint. Only 41 sites actually enrolled patients. The three sites responsible for the earlier phase I / II trial enrolled 26% of the total patients. Only eight sites enrolled > 3 patients. The leading enrollment centers were more likely to have a gynecologic oncologist as the principal investigator who carried out the cytoreductive surgery and delivered the subsequent chemotherapy himself, rather than a medical oncologist who saw the patient postoperatively in referral for chemotherapy.
There are still many obstacles to overcome before successful gene therapy trials can be carried out on a widespread basis including: IRB and regulatory issues, duration of follow -up, physician and patient acceptance of complex treatment regimens.
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The mda -7 tumor suppressor is a novel cytokine in the IL -10 family The melanoma differentiation -associated gene 7 ( mda -7 ) was originally isolated from human melanoma cells induced to undergo terminal differentiation by interferon and mezerin. Introduction of MDA -7 into cells using the replication -deficient adenovirus ( Ad -mda7 ) results in growth inhibition and apoptosis in a broad spectrum of cancer cells, including those of breast, lung, colorectal, and melanoma origins. The cell -killing activity of Ad -mda7 is tumor -selective as normal human cells were resistant to Admda7 -induced cell death. The anti -tumor activity of Ad -mda7 has been confirmed using xenograft models in nude mice. Although it is still not clear how MDA -7 triggers growth inhibition and apoptosis, accumulated evidence suggests that MDA -7 activates genes important for the onset of apoptosis.
Lysates from Ad -mda7 transduced cells showed the predicted intracellular 23 -kDa MDA -7 protein; however, a soluble 40 -kDa form of MDA -7 was also secreted into the media. Sequence and structural analyses revealed MDA -7 protein is a novel member of the interleukin -10 ( IL -10 ) family. The mda -7 gene locus has been localized to chromosome 1q32 and neighbors the IL -10 locus at 1q31 / 32. Additional IL -10 homologs, including IL -19 and IL -20 also map to this region. At a structural level, the MDA -7 protein appears to share the 6 -helical configuration of IL -10.
Preliminary data indicate that human MDA -7 protein does not share the immunosuppressive properties of IL -10, and appears to function in a Th1 manner. MDA -7 expression is induced in PHA -stimulated lymphocytes, and r.hMDA -7 treatment of PBMC results in secretion of IL -6, gamma -IFN and GM -CSF. Therefore, mda -7 appears to be a novel IL -10 homolog with pro -apoptotic properties.
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Egr-1 is a tumor suppressor inhibited in fresh human gliomas strictly alternative to p53 mutation '' We measured Egr -1 and monitored the p53 regulatory pathway by determining the genetic status of p16 / INK4a / ARF and Mdm2 and the sequence of p53 in 31 fresh human gliomas. Amplification of Mdm2 -which binds and inactivates p53 -was observed in three cases. The deletion of p16 / INK4a gene -which restores p53 function by binding Mdm2 -was found in five separate cases. Inactivating mutations of p53 were observed in 10 other cases. Thus, these three mechanisms of p53 inactivation occurred in a strictly mutually exclusive pattern among the 31 gliomas accounting for 58%. The accurate detection of this pattern provides a basis for assessing whether Egr -1 as part of the p53 regulatory pathway. Egr -1 expression was suppressed by over 90% in all 21 cases not involving p53 mutations. This supports the conclusion that Egr -1 is a tumor suppressor factor that acts independent of Mdm2 and ARF. Conversely, Egr -1 protein expression was regularly expressed ( average 66% ) only among the gliomas with inactivating p53 mutations. This result suggests that the suppressor activity of Egr -1 is not a target of inhibition during tumor progression if p53 has been inactivated by mutation but does remain an independent target of inhibition if the p53 pathway has been inactivated by amplification of Mdm2 or deletion of ARF. Native p53 protein may be required for the suppressive function of Egr -1.
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Inhibition of human chorionic gonadotropin -subunit modulates the mitogenic effect of c-myc in human prostate cancer cells Gayathri R. Devi*, Jennifer R. Oldenkamp, and Patrick L. Iversen AVI BioPharma Inc. Corvallis OR 97333. Human chorionic gonadotropin ( hCG ), a placental hormone, also acts as a growth factor and angiogenesis -stimulatory factor in neoplastic transformation of cells. One of the downstream effects of hCG signaling through the G -protein coupled pathway of signal transduction is activation of c -myc oncogene. Amplification and overexpression of c -myc oncogene is a critical factor in prostate cancer pathogenesis. In this study, the effect of inhibition of -hCG and c -myc, singly or in combination was evaluated in DU145 ( RB À / À , p53 À / À , androgen -independent ), and LNCaP ( Rb + / + , p53 + / + , androgen -sensitive ) human prostate cancer cell lines. The target proteins were inhibited in prostate cells by using specific phosphorodiamidate Morpholino antisense oligomers ( PMO ). PMOs represent a novel antisense oligomer chemistry and unique mechanism of action which provide greater stability, longer half -life and are devoid of non sequencespecific properties like phosphorothioate oligonucleotides. Cell morphology and viability were studied which confirmed that the oligomers can be efficiently delivered with low cell toxicity into prostate cancer cells by physical and / or charge -based delivery techniques. Antisense PMOs directed against -hCG and c -myc cause specific decrease of the target protein levels. Unlike LNCaP cells, DU145 cell growth was refractory to cmyc inhibition. Unresponsiveness to c -myc inhibition in DU145 cells was overcome by targeting both -hCG and c -myc genes, resulting in potentiation of the anti -proliferative effect seen with inhibition of -hCG alone. The present study demonstrates the cross -talk between -hCG and c -myc signaling pathways in prostate cancer. The inhibition of -hCG sensitizes prostate cells to the antiproliferative effects of c -myc inhibition, including cells which are refractory to c -myc decrease alone. These data establish the feasibility of a novel combination gene therapy for prostate cancer which involve targeting c -myc and hCG using morpholino antisense oligomers. Supported by the DOD grant DAMD17 -01 -1 -0017.
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Using adenovirus -mediated transfer of a murine FasL-GFP fusion gene to induce apoptosis in brain tumor cells Side effects of these procedures are severe and the prognosis is often poor. Vector -mediated transfer of therapeutic genes into tumors may provide an alternative treatment strategy, with the advantages of reduced toxicity and minimal surgical damage to normal brain tissue. In this report, we investigated the feasibility of forcing brain tumor cells to undergo apoptosis by transferring an apoptotic pathway -inducing signal protein into them. We designed a Fas ligand -Green Fluorescent Protein ( FasL -GFP ) fusion protein which has the properties of being fluorescent, membrane -associated and capable of efficiently delivering an apoptotic signal to neighboring cells. Delivery of this protein using an adenoviral vector induced apoptosis in tumor cells from six different astroblastoma and glioblastoma isolates. Maximum effect was observed between 24 and 48 hours post -transduction. Comparison of transduced vs. apoptotic cell numbers revealed a strong bystander killing of tumor cells, consistent with the model of membrane expression of FasL -GFP causing death in the neighboring cells through the FasL -Fas interaction. In vivo studies using nude mice implanted subcutaneously with brain tumor cells showed efficient inhibition of tumor growth by Ad -mediated FasL -GFP transduction, with reductions in tumor sizes of over 80%. Our results suggest that adenovirus -mediated transfer of FasL -GFP fusion protein may be considered as a potential application for gene therapy of brain tumors.
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Induction of PCD in acute promyelocytic leukemia ( APL ) after combined administration of chemogene treatment consisting of recombinant PML adenovirus and vinorelbine tartrate ( rAVT ) formation and transcription activity functioning as a tumour suppressor. APL cells overexpressing PML due to mutations are resistant to a wide variety of cell death stimuli such as site -specific ligands, receptors and cytokines, disruption of dominant fusion leukemogenic proteins, chromatin remodeling and combining the above with cytotoxic chemotherapy. Bone marrow aspirates were obtained from a patient with APL. Analysis with PCR has exhibited mutations of PML causing its inactivation. Recombinant adenovirus carrying wt -PML was constructed and incubated with APL. Ad -PML effectively infected the APL cells and a high level of PML protein was expressed after 24 hours post -infection retaining a detectable level for 2 weeks. Cytofluorometric analysis exhibited positive expression of differentiation antigen CD11b which correlated with the expression level of PMLmRNA. Treatment with vinorelbine has caused a cell cycle arrest at G2 / M by polymerizing cytoplasmic microtubules. An enhanced expression of p53 and p21 was observed. Morphological analysis with transmission electron microscope has exhibited irreversible apoptotic signs of D2 stage of APL cells leading to a bystander killing effect where apoptotic bodies are phagocytosed by adjacent tumour cells. Metabolic activity by MTT and DNA synthesis by BrdU of treated cells were greatly reduced compared to controls. Concluding, our research work suggests a potential application of combined treatment with Ad -PML and vinorelbine -tartrate against human APL.
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Evaluation of the bystander effect following delivery of a FasL Containing Adenovirus into Prostate Cancer ( PCa ) Cells . Our current focus is to determine if a Bystander Effect is elicited by apoptotic vesicles generated from AdGFPFasL TET infected PCa cells. Using centrifugation, we have isolated apoptotic bodies / cellular debris from AdGFPFasL TET infected PPC -1 and DU145 PCa cells and called this material P1. In co -incubation experiments, P1 induces significant Bystander killing in PPC -1 and PC -3 target cells but not in DU145 cells. The mechanism of Bystander killing in PPC -1 cells is caspase -dependent because it can be blocked using the pan spectrum caspase inhibitor Z -VAD -FMK. More specifically, this mechanism appears to be primarily Fasmediated because Bystander killing is significantly reduced using the antiFas neutralizing antibody ZB4, and P1 induces a Bystander Effect in Jurkat cells, which are Fas + , but not in K -562 cells ( Fas À ). DU145 cells are resistant to P1 Bystander killing which correlates with their sensitivity to exogenously applied Fas agonists. Fas and P1 resistance in DU145 cells may involve the anti -apoptotic inhibitor c -FLIP because we have observed that internally expressed FasL ( using AdGFPFasL TET ) causes FLIP cleavage and perhaps consequently, cell death. In summary, PPC -1 and PC -3 target cells, but not DU145 cells partake in Bystander killing. Supported by CA69598.
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Gene chip analyses with Egr-1 knockout MEF reveal mediators of growth suppression by Egr-1 Purpose: p16 is a tumour suppressor that is known to inhibit the cell cycle at the G1 phase. Frequent aberration of p16 and down regulation at both the mRNA and protein level in nasopharyngeal carcinoma ( NPC ) implicates the significance of p16 in the development and progression of this disease. As a result, selective p16 gene replacement strategy could be potentially effective in stabilizing or even obliterating NPC cells. Adenoviral -p16 gene transfer has been successful in many other human cancer models, such as breast, lung, and prostate, in effecting cell cycle arrest, tumour growth delay and even apoptosis.
Material and Methods: Two ÁE1 / ÁE3 adenoviruses were employed in this study: one with the therapeutic p16 gene ( adv.p16 ), and the other with the reporter -galactosidase ( adv. -gal ), both driven by the CMV promoter. Two EBV-negative NPC cell lines with differential endogenous p16 status, CNE -1 ( low ) and CNE -2Z ( high ), were evaluated. The therapeutic effect of irradiation ( 2Gy ), in conjunction with p16 gene transfer, was examined. Cytotoxic effect was assessed by the clonogenic assay. Cell cycle analysis using flow cytometry, and acridine -orange / ethidium -bromide staining ( AO -EB ) were conducted to determine the effects on cell cycle distribution and apoptosis, respectively. In order to determine the expression of p16 and pRb ( a downstream effector of p16 ), and their kinetics upon infection, Western blot analyses were performed.
Results: Western blotting revealed an increase in p16 expression 4 hours after adv.p16 infection in CNE -1 cells. In contrast, in CNE -2Z cells, the rise in p16 level was not detected until 24 hours after infection. pRb expression was inversely related to that of p16 for both cell lines. While p16 gene transfer was shown to be significantly cytotoxic to CNE -1 cells with a surviving fraction of 0.01% ( 25 pfu / cell of adv.p16 ), CNE -2Z cells were much more resistant ( 10% ) at iso -equivalent doses. Radiation ( 2Gy ) had an additive cytotoxic effect to adv.p16 in CNE -1 cells with a further reduction in survival by 1 log. Results from cell cycle analysis demonstrated an 11% increase at the G0 / G1 phase after 2pfu / cell of adv.p16, whereas no significant increase in apoptosis was observed in the CNE -1 cells.
Conclusion: We have demonstrated that adv.p16, in combination with irradiation, is potentially efficacious in NPC, where p16 expression is absent in a significant majority of patient tumours. ( Cytometry, 38, 201 -203, 1999 , and unpublished ). Since p53 regulates the transcription of many genes, we asked whether measurement of additional p53 regulated genes would increase the sensitivity of the assay or add any information. Materials and Methods: As a model, we used the ovarian line MDAH 2774 and multiparametric flow cytometry to study the kinetics of expression of p53, MDM2, and p21Waf1 / CIP1 ( p21 ) following Ad -p53 treatment in vitro.
Results: p53 transduction resulted in a 3 -fold increase of MDM2 over baseline whereas the p21 expression increased 17 -fold 12 hours post infection. Subpopulation analysis defined three relevant populations post infection ( p21 b / mdm2", p21" / mdm2 b , p21" / mdm2" ) in the p53 -induced population ( b = baseline, " = elevated ). Of these, the p21 / MDM2 double elevated cells were a minor component and may represent experimental error. Thus, p53 mediated p21 and MDM2 expression appeared to be mutually exclusive. Related cell cycle experiments ( simultaneous measurement of p53, [ p21 or MDM2 ], and DNA content ) showed an absence of S phase cells in induced p21 expressing subpopulations whereas MDM2 positive cells were enhanced for the S -phase fraction. In all triple -labeling experiments, p21 was the most sensitive marker for Ad -p53 transduction and activity of the wild -type p53 gene. Quantitative RT-PCR of sorted cell populations supported this idea with a 15 -fold increase of the Ad -p53 mRNA in the p53 b / p21" population. Finally, correlated light scatter, p21, and MDM2 measurements showed that p21 was significantly associated with cell viability whereas expression of MDM2 was associated with cell death.
Conclusion: These data suggest: ( 1 ) the combined measurements of p53, p21, and MDM2 add information to the system at the cellular level, i.e., the multiparametric measurements by flow cytometry are not redundant, and ( 2 ) in cells expressing mutant p53 at high levels, p21 is a more sensitive marker for p53 transduction and activity than either p53 and / or MDM2. Kinetic analysis indicates the following sequence as a working hypothesis:
PD -27
Differential ubiquitination of ribosomes from transformed and normal prostate epithelial cells
Jean Spence and Dan Mercola
Sidney Kimmel Cancer Center, 10835 Altman Row, San Diego, CA. Cancer is considered to be the combined effect of uncontrolled growth and the suppression of apoptosis pathways that would normally be activated by alterations in growth control. Alterations in transcription, translation and protein stability may contribute to the differences between normal and transformed cells. The c -jun N -terminal kinase ( JNK ) signaling pathway can potentially affect protein expression and activity at these levels. We are investigating the modification of ribosomes by ubiquitination during transformation and apoptosis and the role of the JNK pathway in regulating ribosomal ubiquitination.
In this study, we use the prostate cancer cells line, PC3, that stably expresses a dominant negative mutation of c -jun, the biological target of JNK, that has two point mutations converting serines 63 and 73 to alanines. PC3 cells that are stably transformed with junAA fail to undergo apoptosis after treatment with anisomycin and ultraviolet light. Moreover, they are defective for the formation of ubiquitin conjugates associated with ribosomal pellets from growing cells or cells induced to undergo apoptosis. Experiments with the prostate epithelial cell line 267B, and the transformed derivative, 267B -Ki -Ras, demonstrate the some of the ubiquitin chains are associated with ribosomes and that ribosomes from transformed cells are differentially and more heavily ubiquitinated. Two dimensional gel analysis of sucrose gradient purified ribosomes from 267B cells and Ki -ras transformed 267B cells demonstrate that different proteins are targeted for ubiquitination in the two strains during normal growth and apoptosis. Experiments are underway to determine if this differential ubiquitination is under the control of the JNK pathway and dependent on phosphorylation of serines 63 and 73 of c -jun.
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Ad -PTEN: A novel anti -melanoma agent in vitro S8 CONFERENCE ABSTRACTS unusual dual specificity for both proteins and lipids. Mutations of PTEN have been found in a variety of human cancers including glioblastoma, prostate, endometrial, breast, lung, and melanoma. We report here that adenoviral transfer of PTEN into melanoma cells containing wild -type PTEN alleles led to apoptosis and growth inhibition. Phosphorylation of AKT, a key molecule governing cell survival, was diminished following PTEN overexpression. Ad -PTEN transduction also suppressed cell invasion in metastatic melanoma cells. Concomitantly, the level of Ecadherin expression on the cell surface was also increased. Immunohistochemical analyses and confocal microscopy have localized PTEN to the cellular membrane and the cytoplasm. These studies indicate that Ad -PTEN has both pro -apoptotic and anti -metastatic properties, and may be a promising agent for the treatment of melanoma.
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Effects of 4 -HPR in normal, immortalized human ovarian epithelial cells and ovarian carcinoma cells into 5 Fluorouracil ( 5FU ), in an adenoviral vector, breast and ovarian cancer cell lines but not minimal deviation fibroblast cell lines were sensitized to the effects of 5FC in vitro and in human tumor xenograft models. The next experiment was to place the E1A viral gene under the control of the Lplastin promoter to create an adenoviral vector which was conditionally replication competent in tumor cells. We were able to show that this vector was directly cytolytic to breast and ovarian cancer cell lines in vitro, but was not toxic to melanoma cell lines. In contrast, when the melanoma -specific tyrosinase promoter and enhancer were placed 5 0 of the E1A gene in an adenoviral vector, the vector so created was directly cytolytic to melanoma cell lines but not to ovarian and breast cancer cell lines. This specificity of the cytolytic action was also seen with intratumoral injection of vectors carrying an E1A gene driven by either the tyrosinase or the L -plastin promoters in SCID mice with subcutaneous nodules of human melanoma or breast cancer cell lines. Now, a bicistronic adenoviral vector has been created which contains the L -plastin promoter driving a cytosine deaminase gene linked to the E1A gene by the IRES element. The toxicity of this vector to breast and ovarian cancer cells will be compared to vectors with either the cytosine deaminase gene or the E1A gene alone. Other methods of targeting vectors to neoplastic tissues and sparing the normal tissues with adenoviral vectors will also be discussed.
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Systemic administration of replication -selective adenoviruses Given the clear documentation of safety and feasibility with this approach following intravascular administration, but the lack of significant single agent efficacy to date with dl1520, we carried out preclinical studies of intravenous treatment with a significantly more potent adenovirus dl922 / 947 ( E1A mutant ) in nude mouse -human tumor xenograft models; antitumoral efficacy was significantly superior to dl1520 in all models, and equivalent to or even superior to wild -type adenovirus i.v. The replicationselective virus approach has promise as a systemic treatment for cancer.
Acknowledgements 
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Genetically retargeted adenovirus vectors for human gene therapy Increasing the tumor selectivity of adenovirus ( Ad ) vectors for cancer gene therapy has the potential to make these vectors safer, enhance their efficiency, and potentially enable their efficient systemic administration using diverse anticancer genes. Since the first publications on adenovirus targeting, numerous investigators have shown that targeting is technically feasible and functionally important. This knowledge provides us with the molecular understanding to retarget adenovirus. The challenge of future targeting efforts is to assemble the basic components for a ''turn -key'' approach to targeted vector design. To implement this turn -key system three basic components are needed. First, a base vector is necessary in which both the CAR and integrin receptor interactions have been stripped away. This base vector then serves as a platform for the addition of tissue -specific ligands. Second, special production cell lines are required for the propagation of targeted vectors that lack CAR and integrin binding. The final component is a rapid ligand identification system that enables tissuespecific vectors to be rapidly identified. Towards this turn -key system, we have succeeded in generating genetically modified adenovirus vectors stripped of CAR and integrin binding. These vectors are produced in a novel cell line that expresses an artificial receptor capable of binding to CAR and integrin -ablated vectors. When injected intravenously, CAR and integrinablated vectors carrying a luciferase marker gene demonstrate up to 1000 -fold reductions in liver transduction compared to an unmodified vector. These dramatic reductions have been confirmed using GFP -expressing constructs and demonstrate that the ablation of native receptor binding is effective in preventing uptake by non -tumor cells in vivo. In parallel with these studies we have also been developing a novel ligand identification technology called AdDisplay that will enable us to rapidly identify tumorspecific ligands and vectors. This system has advantages over traditional ligand identification technology such as phage display. Using AdDisplay, the peptide ligand is identified in the context of the CAR and integrinablated adenovirus particle. In addition, AdDisplay permits effective selections in mouse xenograft models for adenovirus vectors that home to tumors. We will show our progress using this system and present in vivo data demonstrating proof of principle for tumor targeting using CAR and integrin -ablated adenovirus vectors.
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A phase I /II dose finding trial of the intravenous injection of Cv787, a prostate specific antigen -dependent cytolytic adenovirus in patients with advanced hormone refractory prostate cancer (Hrpc ) 11 . Pharmacokinetic studies indicate peak virus levels within the first hour after injection with a rapid clearance from the blood; a secondary viral peak indicative of in vivo viral replication is seen in most patients beginning about 3 days after administration. Stable PSA and < 50% declines of PSA were observed in eight patients. These data indicate that systemic administration of CV787 is safe, with an acceptable toxicity profile, and that adequate levels of viremia which may be due to in vivo replication are achieved. The modest effect on PSA observed to date suggests biologic activity. Once the single IV dose MTD is reached or the maximal dose of 1Â10 13 VP, phase I / II trials of multiple doses of CV787 in combination with chemotherapy are planned. ( This study was sponsored by Calydon, Inc., which was acquired in August 2001 by Cell Genesys, Inc. ).
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Intra -arterial administration of a replication -selective adenovirus CI -1042 ( Onyx -015) in patients with colorectal carcinoma metastatic to the liver: safety, feasibility and biological activity S10 CONFERENCE ABSTRACTS clinical hepatotoxicity were identified following Onyx -015 infusion. Mild to moderate fever, rigors and fatigue were the most common adverse events. Antibody titers to adenovirus increased significantly in all patients. Expression of IL -1, -6, tumor necrosis factor and interferon -gamma increased within 3 hours and IL -10 by 18 hours. One patient was followed carefully during four consecutive treatments and demonstrated marked increases in circulation levels of interferon gamma, TNF and IL -6. Despite high levels of neutralizing antibody, interferon and TNF, viral genomes were detected in the blood of this patient for 2 to 9 days following each infusion of Onyx -015. Objective responses were demonstrated in combination with chemotherapy, including one patient who was refractory to both 5 -FU and Onyx -015 as single agents. Of the 33 patients enrolled in the study, six patients were treated in the dose escalation phase and 27 patients were treated at the highest administered dose level. The median survival of the patients who received the highest doses of Onyx -015 is 342 days compared to the median survival of 155 days in the patients treated during the dose escalation phase of the study. Hepatic artery infusion of the attenuated adenovirus Onyx -015 was well tolerated, there were no dose -limiting toxicities and there was evidence of infection, replication and antitumoral activity.
1 Chinese University of Hong Kong. Purpose: We have recently achieved nasopharyngeal carcinoma ( NPC ) -specific gene expression by harnessing the exclusive presence of the Epstein -Barr virus ( EBV ) in NPC cells. This strategy was attained by modifying the promoter with the addition of family of repeat ( FR ) sequences, which serve as a transcriptional enhancer, upon binding by EBNA1, an EBV gene product expressed in NPC cells. This targeted strategy allows us now to utilize more ''toxic death'' genes, such as FasL. An additional safety feature was implemented by mutating FasL with an AA 103 -136 deletion, which spans the putative cleavage sites for the generation of soluble FasL ( sFasL ). By preventing the formation of sFasL, the risk of hepatotoxicity of FasL gene therapy can be reduced.
Materials and Methods: The transcriptional cassette of the FR element along with a basal CMV promoter was cloned in juxtaposition to either the luciferase reporter, or the ncFasL ( non -cleavable ) therapeutic gene resulting in the generation of ÁE1 adv.oriP.luc and adv.oriPncFasL. The EBV-negative CNE -2Z, and the EBV-positive C666 -1 cells were evaluated. FasL protein expression was examined using Western blot ( Santa Cruz ); cell viability was assessed with the MTT assay. Cells were also stained with acridine -orange / ethidium bromide to quantitate the proportion of cells undergoing apoptosis.
Results: Infection with adv.oriPncFasL resulted in a dose -dependent increase in FasL expression only in the C666 -1 cells. A dose -dependent reduction in viability was observed for the C666 -1 cells, with 9% survival 6 days after exposure to adv.oriPncFasL ( 25 pfu / cell ). The addition of 6 Gy delivered 24 hours post infection further reduced survival to 0.8%. The shapes of the two survival curves suggested a more -than -additive cytotoxic interaction between the two modalities. The proportion of apoptotic cells increased from 3% ( control ) to 41% with adv.oriPncFasL ( 25 pfu / cell ), which increased slightly to 47% with the addition of 6 Gy. Minimal cytotoxicity ( < 10% ) was observed when C666 -1 cells were treated with adv.oriP.luc, or when EBV-negative CNE -2Z cells were exposed to adv.oriPncFasL.
Conclusion: We have successfully developed a novel adenoviral vector that incorporates EBV-specific gene expression of a mutant FasL, which achieved significant cytotoxicity, mediated primarily by apoptosis. This therapeutic strategy can be potentially applied to all EBV-associated human malignancies.
This study was funded by the Canadian Institutes of Health Research.
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Transcriptional control of adenovirus E1A /E1B bicistronic cassette increases selectivity of viral replication towards targeted cancer cells
Yuanhao Li, Pinky Amin, Nagarajan Ramesh, and De -Chao Yu Cell Genesys, Inc., 342 Lakeside Dr., Foster City, CA 94404. Adenovirus 5 ( Ad5 ) E1A / E1B genes are the first viral genes to be transcribed after viral infection. We have developed oncolytic viral products by placing tissue -or tumor -specific transcriptional regulatory elements ( TRE ) in front of E1A and / or E1B genes in order to target viral replication to specific cancer cells We have used -fetoprotein ( AFP ) -TRE to construct hepatocellular carcinoma ( HCC ) -specific oncolytic adenovirus variants by applying various strategies: AFP TRE controlling E1A alone ( AFP -E1A, CV732 ), E1B alone ( AFP -E1B, CV734 ), or E1A and E1B separately ( AFP -E1A -AFP -E1B, CV733 ). In vitro characterization showed that CV733 has a better tissue selectivity than that of CV732 or CV734. However, due to the existence of dual AFP TREs in CV733, the viral genome appears to be not stable resulting in the deletion of one copy of the AFP -TRE and the E1A gene. To achieve selective replication without viral rearrangement in AFP -producing HCC cells, CV840 ( with E3 deletion ) and CV890 ( wild type E3 ) were created by using single AFP -TRE to control an artificial E1A / E1B bicistronic cassette ( AFP -E1A -IRES -E1B ). In these adenovirus variants, transcription of both E1A and E1B genes is under the control of AFP -TRE. An enlarged E1A / E1B transcript which contains both E1A and E1B messengers was verified by Northern blot. From this large transcript, E1B translation was mediated by an introduced internal ribosome entry site ( IRES ) from encephelomyocarditis virus and the product of E1B was verified by Western blot. Our study suggests that in the single TRE -controlled E1A / E1B bicistronic cassette, the TRE stringently controls both E1A and E1B genes and the IRES can function for E1B translation. In vitro comparison of CV840 / CV890 with CV732 / CV733 demonstrated that CV840 / CV890 efficiently replicate in and destroy AFP -producing HCC cells as well as wild -type Ad5, but replication is highly attenuated by 100,000 times in non -AFP -producing HCC cells or non -HCC cells. The specificity of CV840 / CV890 was 100 -fold higher than CV732 / CV733. Subsequently similar observations were made when two prostate cancer specific variants, CV787 ( PB -E1A -PSE -E1B ) and CV912 ( PSE -E1A -IRES -E1B ) were compared. This new strategy increases the viral specificity and broadens potential applications of our oncolytic adenovirus technology in some cancers wherein the tumorspecific TREs are limited. It also conserves genomic space within the viral genome for introducing therapeutic genes into adenovirus variants in order to achieve significant anticancer efficacy.
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Targeted luminescent adenoviral vectors for ovarian cancer therapy We reasoned that because tumors are made of constantly dividing cells, they would be efficiently transduced only with vector systems allowing transgene propagation. We thus designed two, replicative retrovirus -derived vector systems: one inherently replicative vector and one defective vector propagated by a helper retrovirus. We obtained very efficient transgene propagations in vitro with these two systems. In vivo, we could transduce > 85% tumor cells with replicative vectors, compared to < 1% with defective vectors under similar conditions. Noteworthy, retroviral propagation could be efficiently blocked by azido -thymidine, in vitro and in vivo. Major therapeutic effects were observed only when replicative, but not defective, retroviral vector systems were used treat either subcutaneous or brain tumors with a suicide gene. In the brain tumor model, replicative retroviral vectors were approximately 1000 times more efficient than defective adenoviral vector. We have now improved these first -generation replicative vectors, notably their safety, by the addition of propagation constraints. We likewise obtained replicative retroviruses with LTRs incorporating tissue specific or inducible regulatory sequences. Preliminary results suggest that these second -generation replicative retroviral vectors have a great potential for cancer gene therapy.
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Replication -competent retrovirus vectors targeted to cancer cells achieve highly efficient gene transfer to solid tumors in vivo The inability of conventional replication -defective murine leukemia virus ( MLV ) -based retroviral vectors to achieve effective transduction of tumors in vivo has been a major obstacle in clinical trials of cancer gene therapy. Gene transfer using replication -competent retrovirus ( RCR ) vectors would be more efficient, as each successfully transduced tumor cell would itself become a virus -producing cell and thereby initiate further infection events. While MLV-based RCR vectors for delivery of non -viral transgenes have been described previously, such vectors have usually exhibited rapid rearrangement and transgene deletion within one or two replication cycles.
We have now devised a novel RCR vector design that has proven to be genetically stable over multiple serial replication cycles in cell culture, and can achieve highly efficient delivery of inserted transgenes to solid tumors in vivo in breast cancer, prostate cancer, and glioblastoma models. The RCR vector was undetectable in normal tissues by sensitive PCR assays, presumably due to selectivity for rapidly dividing tumor cells provided by the intrinsic inability of MLV to infect quiescent cells. To further enhance tumor selectivity and minimize the potential risk to normal cells, we have also designed and tested transcriptionally targeted RCR vectors in which key regulatory sequences in the LTR have been replaced with tissue -specific or inducible elements to control replication of the viral genome.
In contrast to oncolytic viruses now in development as cancer therapeutics, MLV-based RCR vectors can replicate without lysis of host cells and spread via direct cell -to -cell budding, and may be less likely to elicit robust immune responses that prematurely terminate virus propagation. After spreading throughout the tumor, all cells infected with RCR vectors carrying a suicide gene can be simultaneously killed by pro -drug administration.
This work was supported in part by grants #BC980554 and #PC991159 from the Department of Defense, and NCI grant #P01 CA59318.
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Retrovirus and lentivirus vectors transcriptionally targeted to-and inducible in-epithelial cells mediate specific fusiogenic lysis of carcinoma cells We have previously evaluated the feasibility of direct in vivo retrovirusmediated gene transfer into dog bladder bearing spontaneous carcinomas mimicking human pathology ( Dumey et al ). This is with a view to achieving gene transfer in e.g., superficial bladder tumours cells using clinically relevant procedures. Preferential transduction of malignant cells was evidenced. A next step consists in designing improved vectors addressing tumour cells. SIN derivatives of FOCHA were constructed. An extensive deletion of U3 -sequences which also removes CAAT and TATA box was introduced. LTR regulatory elements have been replaced by defined EGFresponsive sequences of EGF -R enhancer / promoter, to obtain FOCHE2 vector. EGFP1 -transmitting clones ( TE -FLYA and -GA cells, F.L. Cosset ) produce 10 6 Ampho -cfu / mL and 10 5 GALV-cfu / mL, respectively. Expression is: ( i ) absent in non -epithelial cells; ( ii ) EGF -inducible in primary keratinocytes and some fibroblasts; ( iii ) constitutive and stable in a panel of human carcinoma cell lines including colon, pancreas, breast, lung, prostate and bladder; ( iv ) much higher in some of these as compared to FOCHA. A cPPT-SIN lentivirus vector, LIPE2, including the same transcriptional elements as an internal cassette, has also been derived from pRRLSIN -18 / WPRE ( forwarded by Luigi Naldini ). A selective spontaneous fusiogenic effect is monitored in transduced carcinoma cells ( e.g., HTC116 ) as compared to controls, starting at day 12. This is using bicistronic constructs transmitting both HSV-TK* and hu -HFV envelope**. A delayed bystander effect is observed without GCV ( days 12 -15 ). In comparison, early addition of GCV ( days 4 -10 ) results in a much lower effect. Transducedcontrol cells are not affected although being PCR -positive. RT-PCR and immunofluorescence assays for HFV-env document the absence of detectable expression except in those cell -lines were EGF -inducible toxicity is observed following addition of EGF in culture media. These vectors ( i ) mediate efficient and selective cytotoxicity in a wide range of 7 cfu / mL, which were higher than either A375.AMIZ LEN or PA317 LEN. The incidence of high -titer clones produced from the mixed populations of the PA317 -, A375 -, and 293 -based VPC was monitored. Using a method to rapidly screen single -cellderived clones, profiles of LEN clone titers were revealed for each of the retroviral packaging cell lines. Populations of A375.AMIZ and 293.AMIZ retroviral packaging cells yielded distinctly different LEN VPC clone titer profiles based on the single -cell -derived packager line. Effective AMIZ retroviral packaging lines were identified by the predominance of high titer LEN VPC clones, and will be considered for other retroviral -mediated gene transfer applications. Our data suggest that vector production can be increased between two -and ten -fold from the mixed population by identification of the most effective single -cell -derived VPC.
O-42 ICP34.5 deleted herpes simplex virus 1 with enhanced oncolytic and anti -tumour potential: development of novel replicating vectors for tumour therapy HSV in which the neurovirulence factor ICP34.5 is inactivated has been shown to direct tumour specific cell lysis in tumour models both in vitro and in vivo. Such viruses have also been shown to be safe in Phase I clinical trials by intracerebral injection in glioma patients. Previous work has used serially passaged laboratory isolates of HSV-1 which might be anticipated to be attenuated in human tumour cells as compared to more recent clinical isolates. In work aimed at producing viruses with enhanced anti -tumour potential, we have deleted ICP34.5 from a number of HSV1 clinical isolates and compared their replicative and cell killing potential in human tumour cell lines. Such ICP34.5 deleted clinical isolates showed greatly enhanced lytic capabilities in all tumour cells tested as compared to HSV1 strain 17 + , suggesting them to have great promise for cancer treatment. We have further engineered these viruses by deleting the gene encoding ICP47 and to express GM -CSF, both aimed at maximising anti -tumour immune responses following intra -tumoural inoculation, virus replication and accompanying cell death. Experiments comparing these viruses in in vivo tumour models have demonstrated considerable anti -tumour effects in a number of tumour models, and demonstrate that ICP34.5 deleted HSV based on recent clinical isolates of the virus have considerable potential for the treatment of human cancers, either through oncolytic effects alone, or through the co -delivery of anti -tumour or immune stimulating genes which might be expected to synergise with the oncolytic effect.
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Replication selective herpes simplex virus -1 mutant therapy of cervical cancer is enhanced by low dose radiation Cervical cancer is a major health issue worldwide and novel treatment strategies for invasive cervical cancer are needed. Replication selective Herpes Simplex Virus I mutants are promising anti -cancer agents and local therapy could improve the clinical outcome of cervical cancer patients. Here we demonstrate that the replication selective HSV mutants, 4009, 3616 and G207, R7020 are efficacious against cervical cancer. These mutants are attenuated by mutation or deletion of ICP34.5 gene, multiattenuated by deletion of ribonucleotide reductase and ICP34.5 or deletion of the internal inverted repeat ( including one copy of ICP34.5 ), respectively. These four HSV-1 mutants induced significant lysis of three established human cervical cancer cell lines in vitro in a dose dependent manner. G207 intratumoral treatment of established subcutaneous C33a tumors in severe combined immunodeficient ( SCID ) mice significantly reduced tumor burden by 50%. Weekly and triweekly treatments significantly improved efficacy and inhibited flank tumor growth in a dose dependent manner without toxicity. No HSV sequences were detected in brain, liver, kidney, spinal cord, bowel, lung and skin adjacent to tumor by PCR. Low doses of radiation ( 1.5 and 3 Gy ), which could be tolerated by patients with recurrent cervical cancer, significantly augmented the anti -cancer effect in vitro. As a likely contributing factor, low dose radiation increased viral replication greater than 4 -fold in cervical cancer cells. The in vivo effect of G207 combined with low dose irradiation ( 3 Gy ) was studied in Me180 xenografts in athymic mice. Radiation or replication selective HSV viral therapy significantly decreased tumor burden. Furthermore, combination therapy increased the frequency of complete tumor eradication from 0% to 42%. These results suggest that replication selective HSV-1 mutants may be potent oncolytic agents for the treatment of cervical cancer.
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Programmable pharmacokinetics, disease site targeting and tumor specific gene expression of stable plasmid -lipid particles for systemic gene delivery 
O-45
Novel inducible and amplified expression vectors for gene therapy T. C. Tsang, P. Luo, X. He, and D. T. Harris Gene Therapy Group, Department of Microbiology and Immunology, University of Arizona, Tucson, AZ. The ability to express therapeutic gene( s ) at very high levels is important for the success of gene therapy. This goal is especially important in immunebased gene therapy because the anti -tumor effects of cytokines such as IL -2 and IFN -gamma are dose -dependent requiring that a critical ''threshold'' level be reached. Our laboratory has approached this problem by creating new sets of expression vectors using a novel amplifier strategy. The amplifiers consist of a constitutive, inducible or tissue specific promoter controlling the expression of a transcription factor that trans -activates a second promoter( s ) located on the same construct. The second promoter( s ) drives the gene( s ) of interest. An amplifier construct, pHi -2 -IL -2, produced higher levels of IL -2 expression in several human and mouse cell lines as compared to CMV promoter -controlled vectors. In the mouse tumor models B16 ( melanoma ) and LL2 ( lung ), injection of tumor cells transfected with pHi -2 -IL -2 leads to slower tumor growth and longer survival than either wild -type tumors or tumor cells transfected with pCMV-IL -2. To test whether the amplifier strategy can be applied to inducible promoters, we have constructed a new amplifier construct using the heat -shock protein 70 ( HSP70 ) gene promoter and HIV 2 LTR / TAT, pHi -Hot -MCS. In B16 and LL2 cells transfected with pHi -Hot -IL -2, treatment for 30 minutes at 428C increased IL -2 levels 16 -and 63 -fold higher than unheated controls. These levels are 35 and 38 times higher than a control construct in which the IL -2 gene was placed under the control of the HSP70 gene promoter directly. Remarkably, the heat induced IL -2 levels were 29 -and 36 -fold higher than those achieved by the CMV promoter, thus making pHi -Hot the strongest inducible promoter known so far. Finally, in vivo, heating of the LL2 tumors transfected with pHi -Hot -IL -2 caused the tumors to regress, leading to prolonged survival. These results suggest that the amplifier concept may be useful in developing future highlevel gene therapy vectors.
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Analysis of adenoviral and adeno-associated viral vector transduction efficiency in human cell lines, glioblastoma biopsy spheroids and xenograft models Recombinant Adenoviruses ( ADV ) and Adeno -associated viruses ( AAV ) encoding reporter genes were assessed for transduction of the reporter genes into: 1 ) glioma and mammary cancer cell lines grown as monolayers, 2 ) spheroids derived from glioblastoma specimens, and 3 ) human glioblastomas xenografted into the nude rat brain. Virus particles were added in media containing serum or PBS for in vivo injections and transduction efficiency was assessed by immunostaining, confocal microscopy and flow -cytometry. To obtain a comparative profile, all flow cytometry experiments with ADV and AAV were performed simultaneously. We detected ADV and AAV viral -mediated GFP transgene expression in all cell lines except for one leukemia -derived cell line. Transduction efficiencies based on flow cytometry experiments varied greatly. In general, breast cancer cell lines were more resistant to either ADV or AAV transduction compared to the glioma cell lines. When we infected human glioblastoma spheroids with ADV or AAV, we observed uniform reporter gene activity ( GFP or lacZ ) across the surface of the spheroid. When spheroids were sectioned, we observed AAV-directed reporter gene activity throughout the spheroid. In contrast, ADV infection was limited to the outer layers, indicating a better penetration by the smaller AAV particle. Xenograft models were established using human glioblastoma spheroids. Two months following stereotaxic injection of AAV-lacZ into the tumor, we observed positive gene expression in many regions of the tumor. Interestingly, transgene expression was localized not only with the site of injection, suggesting spread of the vector. We conclude that AAV vector system is comparable to ADV vectors with regards to transduction efficiency. However, AAV vectors appear to penetrate deeper into tumor tissue, indicating that AAV vectors may have distinct advantages for therapeutic gene delivery to solid tissue like malignant tumors. SV40 in vitro packaging of plasmid DNA, using recombinant SV40 capsid proteins produced in insect cells, is a very efficient gene delivery system for hematopoietic cells. Using the major capsid protein constituting the outer shell ( VP1 ), or a mixture of four SV40 proteins ( VP1, VP2, VP3 and agno ), different plasmids carrying MDR1 ( a multidrug efflux pump ) or GFP were packaged and delivered into the 0.45 lymphoblastoid cell line. MDR1 expression was determined by measuring rhodamine -123 efflux in the absence or the presence of inhibitors, and by cell surface expression of the gene product, P -gp. The delivery efficiency of all MDR1 -plasmids up to 15 kb in size was very high -almost every cell expressed P -gp. The level of expression per cell is limited, however, so we sought to determine the route taken by in vitro packaged virions once they enter cells.
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The entry of VP1 + VP3 transducing particles carrying the GFP gene into cells was followed using confocal microscopy ( VP1 or VP3 polyclonal antibodies ). Ten minutes after exposure to pseudovirions, VP1 staining appeared to be localized at the cell membrane. Over a time course of 20 minutes, 60 minutes, 19 hours, 5 days and 2 weeks, particles moved into the cell, to the Golgi ( identified by using a monoclonal antibody, # G2404, Cancer Gene Therapy, Vol 8, Suppl 2, 2001 S14 CONFERENCE ABSTRACTS Sigma, MO ), and eventually accumulated in granules. The membrane staining pattern was still found five days post transduction. No staining was observed within the nucleus. VP3 seemed to enter the cell more efficiently than VP1, and most staining of VP3 was found in granules 19 hours post transduction. Similar patterns were demonstrated in lymphoblastoid cells transduced by wild -type SV40 virions indicating that in vitro -packaged pseudovirions enter cells through a similar pathway to wild -type SV40. We are using FISH analysis to follow the intracellular pathway of SV40 packaged DNA, to determine a possible rate -limiting step for delivery of DNA into the nucleus. Research has shown replication deficient recombinant adenoviral vector particles encoding the p53 tumor suppressor gene ( rAd -p53 ) to be well tolerated in human subjects, and a future therapeutic option for ovarian cancer. To facilitate effective gene transduction of the tumor and surrounding tissues, administration of the active principle should be local to and retained at the site. Intraperitoneal ( IP ) instillation to mouse and rabbit of rAd -gal using a dextrin solution has demonstrated significantly enhanced transgene expression in peritoneal wall and tumor tissue compared with a phosphate buffered saline ( PBS ) solution ( Engler et al, Cancer Gene Therapy 2000; 7 ( 12 ): S13 ). We have now examined in vivo survival following IP rAd -p53 administration in murine xenograft PC3 prostate ( n = 51 ) and 2774 ovarian cancer ( n = 44 ) models resistant to rAd -p53 therapy. Treatment groups comprised dextrin control, untreated control, and 5Â10 10 , 5Â10 9 , 5Â10 8 dose particles ( prostate model ), and 1Â10 10 , 5Â10 9 , 1Â10 9 dose particles ( ovarian model ) using dextrin and PBS delivery solutions. 1 -mL and 0.5 -mL treatments were given on days 9, 11, 14, 15, and 18; and days 2, 5, 8, and 12 ( prostate and cancer models, respectively ) following tumor cell injection. Animals were caged randomly and monitored daily by an observer blind to the treatments for visible body weight loss, hunched back and sedation. Date of sacrifice or death, and gross pathology were assessed. Number of survival days was plotted using a Kaplan Meier curve and analysed using the Logrank Test. At the 5Â10 10 viral particle dose, there was a significant ( p < 0.05 ) increase in survival using dextrin solution ( maximum 100 days, median 53 days ) compared to PBS ( max. 42, median 33 ) and to controls ( max 33, median 30 ). Similar prolongation of survival was observed in the ovarian cancer model when using dextrin delivery solution. These results suggest that a dextrin solution has an enhanced ability to deliver genetic material to cells in the peritoneal cavity, resulting in increased transgene expression and prolonged animal survival. BioVex Ltd, The Windeyer Institute, London W1T 4JF, UK. We have found that HSV infects dendritic cells ( DC ) at very high efficiency ( > 70% transduction at MOI = 1 ). This provides the potential to use HSV to deliver genes to DC for the immunotherapy of infectious disease or cancer. However, DC infected with HSV usually lose the ability to become activated by either HSV infection or other stimuli, and cannot therefore, induce effective T-cell responses. We have found that this DC inactivation is mediated by the HSV vhs protein and thus that vhs is likely to usually be important for immune evasion by the virus. Deletion of vhs allows the development of HSV vectors which can transduce DC at very high efficiency and which activate DC following transduction. These vectors allow the stimulation of antigen specific T-cell responses, allow highly effective DC trafficking to lymph nodes following transduction, and can easily be engineered to express multiple disease -associated antigen genes. These vectors are in development for the in vivo and ex vivo immunotherapy of cancer and infectious disease via co -delivery of multiple relevant antigens to DC and have unique potential for the development of efficient and practical DC -based immunotherapy approaches to disease treatment.
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Differential effects of integrin-activating manganese and cytokines on adenoviral gene transfer into human ovarian and cervical cancer cells METHODS: Adenovirus -mediated transgene expression was monitored by using a beta -galactosidase -expressing adenoviral vector ( AdGal ). Localization of integrins was performed by immunofluorescence analysis.
RESULTS: Manganese chloride increased adenoviral transduction efficiency ( ATE ) in three of four ovarian cancer cell lines and in HeLa cells. Ovarian cancer cell line OV-MZ -30 displayed poor ATE while expressing CAR and integrins at high levels. In these cells, manganese chloride resulted in a five -fold increase of beta -galactosidase activity. ATE was not increased in OV-MZ -21 lacking adenovirus -binding integrins. The cytokine TGF -beta increased integrin alpha 5 expression and reduced cancer cell proliferation, with little effect on ATE in HeLa and eight ovarian cancer cell lines tested. In HeLa and OV-2774 cells, ATE was reduced after pretreatment with TGF -beta. Fibrogenic TGF -beta induced a spindleshaped cell morphology, concomitant with enhanced matrix adhesions. Trypsinization of ovarian and cervical cancer cells resulted in dispersion of integrin alpha V beta 3 from matrix adhesions to an overall membrane distribution. Trypsinization increased ATE up to 20 -fold.
CONCLUSION: Adenoviral gene transfer into ovarian and cervical cancer cells can be increased ( 1 ) by trypsinization, ( 2 ) by manganese chloride possibly through stimulation of ligand -binding activity of integrins, ( 3 ) but not necessarily by integrin -stimulating TGF -beta.
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Adeno -associated viral vector 2, 4 and 5 transduction efficiency in breast carcinoma-and glioma -derived cell lines and spheroids derived from human glioblastomas NIH, Laboratory of Biochemical Genetics, Bethesda, MD. We have examined the suitability of recombinant Adeno -associated viruses ( AAV ) serotypes 2, 4, and 5 for cancer gene therapy. We generated AAV vectors encoding GFP and lacZ reporter genes and transduced twelve glioma and breast cancer cell lines grown as monolayers as well as spheroids derived from human glioblastoma biopsy specimens. Virus particles were added in media containing serum. The transduction efficiency, as measured by reporter protein activity, was assessed by immunostaining, confocal microscopy and flow -cytometry. In general, the appearance of reporter Cancer Gene Therapy, Vol 8, Suppl 2, 2001 CONFERENCE ABSTRACTS S15 protein activity was detected earlier in experiments using AAV2 vectors compared to the AAV4 or AAV5 serotypes. Furthermore, AAV2 vectors transduced a broader range of breast and glioma cell lines compared with AAV4 or AAV5 vectors. Transduction efficiencies were quantified by flow cytometry experiments and varied greatly at the same multiplicity of infection. We also infected human glioblastoma biopsy spheroids with the AAV serotype 2, 4 or 5 vectors. Following a period of incubation for up to one month, we observed positive signals from all AAV serotypes. However, AAV2 vectors appeared to transduce more cells than either the AAV4 or AAV5 serotypes. We conclude that AAVs may represent an efficient vector system that can target different types of solid tissue. Taken together, these results suggest a positive role for AAV technology in oncological therapeutic gene delivery.
PD -52
Anti -tumor efficacy employing oncolytic adenovirus specific for hepatocellular carcinoma Yuanhao Li, Yu Chen, Pinky Amin, Daniel Henderson and De -Chao Yu Cell Genesys, Inc., 342 Lakeside Drive, Foster City, CA 94404. Hepatocellular carcinoma ( HCC ) is the third leading cause of cancer death in the world. Tumor resection remains the only curative treatment but is often not possible and frequently unsuccessful. -fetoprotein ( AFP ), a tumor marker currently used for the diagnosis and management of HCC, is an oncofetal protein expressed in a majority of HCCs, but rarely in normal hepatocytes. Since AFP gene expression is tightly regulated at the level of transcription, AFP transcriptional regulatory elements ( TRE ) are excellent candidates for generating HCC -specific oncolytic adenoviruses. CV890, an HCC specific oncolytic adenovirus variant was constructed by employing an AFP -TRE to control an artificial E1A -IRES -E1B bicistronic cassette. CV890 efficiently replicates in and destroys AFP -producing HCC cells ( HepG2, Huh7, Hep3B, PLC / PRF / 5, SNU449 ) as well as wild -type Ad5, but replication is highly attenuated in non -AFP -producing HCC cells ( SkHep -1, Chang liver cell, LNCaP, HBL -100, PA -1, UM -UC -3, SW 780, Colo 201, and U118 MG ) or non -HCC cells ( Human primary lung fibroblast, bladder smooth muscle and mammary epithelial ). CV890 produced 100,000 -fold less virus than wild -type Ad5 in non -AFPproducing cells. In vivo, anti -tumor efficacy of CV890 was examined in BALB / c nu / nu mice containing large subcutaneous HepG2 or Hep3B tumor xenografts. Tumor volume of distant xenografts dropped below baseline 4 weeks after a single IV injection. To obtain best therapeutic regimen, CV890 was tested for synergy with different chemotherapeutic agents via in vitro cell based assay and in vivo animal model testing. Our study demonstrated that combination of CV890 with doxorubicin has synergistic antitumor efficacy, yielding complete elimination of distant Hep3B tumors 4 weeks following a single intravenous administration of both compounds. These results support the clinical development of CV890 as an antineoplastic gent for the treatment of localized or metastatic HCC.
PD -53
Identification of human uroplakin II promoter and its use in the construction of a urothelium -specific adenovirus variant that eliminates established bladder tumors in combination with docetaxel Jane Zhang, Nagarajan Ramesh, Yu Chen, Natalie Nguyen, and De -Chao Yu Cell Genesys, Inc., 342 Lakeside Drive, Foster City, CA 94404. Human uroplakins ( UPs ) are a group of integral membrane proteins that are synthesized as the major differentiation products of mammalian urothelium. Recent observations have indicated that the uroplakin II ( UPII ) protein may be an important marker for bladder cancer ( Wu et al, 1998, Cancer Research 58: 1291 -1297 ). Although Uroplakin II gene expression has been shown to be bladder specific and differentiation dependent, very little is known about its transcription response elements. In order to identify the promoter elements, a DNA fragment of 2239 base pairs ( bp ) upstream of the UPII gene was amplified by polymerase chain reaction ( PCR ) and linked to a promoterless firefly luciferase reporter gene. Transient transfection experiments showed that the DNA segment located between À 1809 and + 1 bp, resulted in preferential expression in bladder carcinoma cells with negligible expression in non urothelial cells. This promoter was then engineered into Adenovirus type 5 ( Ad5 ) to drive the expression of the E1A and E1B genes and to create an attenuated replication competent Adenovirus variant CV884. Viral replication, and cytopathic effect of CV884 were examined by virus yield and MTT assays in bladder transient cell carcinoma cell lines RT4 and SW780, non -bladder cancer cell lines G -361, LNCaP, PA -1 and U -118 and human primary cells lung fibroblast, bladder smooth muscle cell and mammary epithelial cell. CV884 was found to replicate and eliminate bladder transient cell carcinoma ( TCC ) efficiently with high specificity ( 10,000:1 ) in comparison to non -bladder cells. Intratumoral administration of CV884 resulted in substantial ( p < 0.01 ) inhibition of tumor growth. Significant in vivo antitumor efficacy was observed when CV884 was combined with doxorubicin and docetaxel resulting in complete elimination of RT4 and SW780 xenograft tumors in nude mice. These results demonstrate the utility of uroplakin II promoter in the generation of urothelium specific adenoviral vectors and the potential foundation for the development of bladder tumor -specific Oncolytic viral therapies.
PD -54
In vitro risk of insertion of vector DNA into genomic DNA after infection of a lung cancer cell line with INGN 201 (Ad -p53 ) Our increasing understanding of the factors which control the decision and execution of programmed cell death has presented a new range of potential targets for gene therapy for cancer. We have developed a series of dominant negative mutant genes to interfere with the survival signals transmitted through the PI -3K pathway activated by growth factor receptors as well as transforming ras oncogene mutations. Using adenoviral vectors to transduce dominant negatives of PI -3K itself, AKT and RAS, as well as the tumour suppressor gene PTEN which is a natural antagonist of this pathway, we have shown that the pathway can be selectively inhibited to induce apoptosis of cancer cells. These constructs also show significant antitumorigenic properties when administered intraperitoneally to animals with malignant ascites.
We have investigated the biology of Bim, a newly reported member of the bcl -2 family with strong pro -apoptotic properties. Multiple isoforms of the gene product exist in human cells and differ in their ability to induce apoptosis. We have identified a novel form which interacts with both bcl -2 and bax, and is capable of inducing apoptosis through either of these proteins. This gene may have potential as an anti -cancer gene therapeutic.
We have explored whether caspases, the effector proteins involved in the destructive phase of apoptosis, can be exploited as gene therapeutics and shown that overexpression of procaspases can enhance the sensitivity of cancer cells to the cytotoxic effects not only of conventional anti -cancer drugs but also of genetic prodrug activation therapy.
Together these approaches confirm that apoptotic pathways can be effective targets for genetic intervention for cancer therapy.
O-56 P450-based cancer gene therapy: recent advances in the laboratory and the clinic Youssef Jounaidi, Pamela S. Schwartz, Jodi Hecht, Chong -Sheng Chen, and David J. Waxman Division of Cell and Molecular Biology, Department of Biology, Boston University, Boston MA 02215. P450 -based cancer gene therapy is a novel prodrug activation strategy for cancer treatment that has substantial potential for improving the safety and efficacy of cancer chemotherapeutics. The primary goal of this strategy is to selectively increase tumor cell exposure to cytotoxic drug metabolites generated locally by a prodrug -activating P450 enzyme. This strategy has been exemplified for the anti -cancer drugs cyclophosphamide and ifosfamide, which are activated by liver P450 enzymes whose expression is generally deficient in tumor cells. Transduction of tumors with a prodrugactivating P450, such as CYP2B6, followed by prodrug treatment, greatly increases intratumoral formation of activated drug metabolites under both hypoxic and normoxic conditions. This leads to tumor cell cytotoxicity via a mitochondrial / caspase 9 -dependent apoptotic pathway without a significant increase in host toxicity. P450 gene therapy is characterized by a bystander cytotoxic response that can greatly increase the therapeutic effect by extending it to include nearby tumor cells not transduced with the therapeutic CYP gene. Further enhancements of P450 prodrug -dependent anti -tumor activity can be achieved by: 1 ) co -transduction of P450 reductase, which further increases the rate of intratumoral prodrug activation; 2 ) selective inhibition of liver P450 -catalyzed prodrug activation; and 3 ) anti -angiogenic scheduling of cyclophosphamide treatment, which substantially magnifies the anti -tumor effect and leads to major regression of established tumors. This cancer treatment strategy can be extended to other P450 -activated anticancer agents, including prodrugs that undergo P450 reductase -dependent bioreductive metabolism. Phase I / II clinical testing in progress has established the safety of P450 gene delivery in a breast cancer trial. Moreover, both safety and a striking increase in efficacy were observed in a pancreatic cancer trial, where a 3 -fold increase in one -year survival rates was recently reported using CYP2B1 in combination with ifosfamide. [ Support: NIH CA49248 ( DJW ) ].
O-57
A minimal promoter region of the c-erbB2 gene that can drive the expression of a suicide gene preferentially in cancer cells The c -erbB2, a receptor tyrosine kinase proto -oncogene product, is overexpressed in 20 -30% of human breast cancer and the overexpression has been shown to correlate with poor prognosis of the cancer patients. Promoter regions of the c -erbB -2 gene have analyzed. However, the feasibility of the promoter to drive a suicide gene in breast cancer specific manner has not been well investigated. In order to clarify the promoter region with transcriptional specificity in breast cancer cells, we isolated 536bp genomic DNA in the 5_( IU_( J -upstream of its transcription initiation site. This fragments were sequentially deleted from 5_( IU_( Jside and were linked with the luciferase gene, and examined luciferase activity by introducing the plasmid DNA into breast cancer and non -breast cancer cells including fibroblast cells. We found that the ( À 256 / + 1 ) fragment gave greater luciferase activity than any other fragments in breast cancer cells. The same fragment showed minimal luciferase activity in nonbreast cancer cells. Transfection of breast cancer cells ( MCF7 ) with Herpes Simplex -thymidine kinase gene linked to the 256 -bp promoter ( 256 -TK ) increased the sensitivity to ganciclovir( GCV ). On the other hand the susceptibility of non -breast cancer cells ( A875 ) transfected with 256 -TK DNA remained unchanged. Subcutaneously xenotransplanted tumors of MCF7 cells which were transfected with 256 -TK regressed and disappeared after the administration of GCV. Gel shift assay revealed the presence of DNA -protein complex that was specific to ( À 256 / + 1 ) fragment and breast cancer cells. These results suggest that the 256 -bp region in the cerbB2 gene can drive a suicide gene preferentially in breast cancer cells.
O-58
Ganciclovir-specific HSV-TKs for characterizing differential cell death mechanisms in colon tumor cells: New treatment options with 5FdU, it was determined that this mutant was not affected by intracellular thymidine metabolites and was functioning as a GCV-specific kinase. Two other mutants were identified that also had minimal thymidine metabolism in cells, but generated much lower cytotoxic levels of GCV metabolites. In comparisons of synchronized cultures of each HSV-TK cell line treated with GCV, the high GCV metabolizers caused complete cell cycle arrest in late S -phase, eventually leading to an S -phase specific apoptosis without progression through mitosis. In contrast, the two lower GCV metabolizing cell lines had partial cell cycle arrests and died via a nonapoptotic pathway following one mitotic division. Phosphorylation of the checkpoint kinase, Chk -1, occurred in response to GCV treatment in the high GCV metabolizing cells, but was attenuated in the lower GCV metabolizing cells. Using a competition assay, we have also shown in vitro that GCV-triphosphate can bind and inhibit GTP binding of p21 -Ras and other GTP binding proteins. The cumulative data indicate that the cellular events associated with GCV-mediated cell death can be modulated depending on the choice of HSV-TK and the resulting intracellular GCV phospho -metabolite levels.
O-59
Intratumoral infusion of DAC -30-liposome -HSVtkgene complex for the treatment of inoperable glioblastoma multiforme ( GBM ) -and non -invasive monitoring of gene expression in patients Most of the clinical suicide -gene -therapy trails for recurrent glioblastomas were done with different viral vectors bearing the herpes simplex thymidine kinase ( HSVtk ) gene. Because of the well known efficacy and immunological problems associated with retro -or adeno -viruses we developed a non -viral gene delivery system that can also be used for a repeat application 1 -3 . A high -flow intracerebral infusion system was used in a phase I / II clinical trial of gene therapy for recurrent glioblastoma in five patients ( age range 49 -67 patients ) to reach a wider area and to interfere with the route of cell invasion. For non -invasive monitoring of the localisation, magnitude and duration of vector -mediated gene expression we used positron -emission tomography ( PET ) with I -124 -labelled 2 0 fluoro -2 0 -deoxy -1 -D -arabino -furanosyl -5 -idodo -uracil ( I 124 -FIAU -a specific marker substrate for gene expression of HSVtk 4 . After biopsy sampling of the tumor, one or two catheters were stereotactically placed within the tumor and subcutaneously connected to a port. This allowed targeted intratumoral infusion of the DAC -30 / HSVtk complexes ( volume 30 mL over 48 hours ). Ganciclovir treatment ( 5 mg / kg twice a day over 14 days ) was started 4 days after vector infusion. Treatment responses were recorded by repeated MRI as well as PET ( FDG; MET-PED, FIAU ). After vector administration, in one of five patients specific [ I 124 ]FIAU -associated radioactivity was observed within the infused tumor. However, the other four patients showed a significantly lower number of proliferating tumor cells per voxel. The therapeutic effect was limited to a part of the tumor. Intracerebral high -flow infusion of DAC -30 -liposome -HSVtk -complex has been well tolerated. Both, the distribution kinetic and tumor response can be improved further by using an optimised treatment schedule. The non -invasive monitoring of the transgene distribution kinetic will have a important impact on the future development of safe and efficient vector application systems.
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Targeted -specific gene therapy for prostate cancer Sun Hye Paik, Mathew Bui, Allan Pantuck, and Arie Belldegrun University of California, Los Angeles, CA. Gene therapy can selectively introduce therapeutic genes into cancer cells. However, a variety of gene therapy properties must be improved to assure efficient and targeted anti -cancer gene delivery. To restrict the therapeutic gene expression to prostate tumor cells, our laboratory have generated an improved prostate specific promoter. Preliminary in vitro studies show that this improved PSA promoter / enhancer construct not only exhibits 19 -fold higher activity relative to the PSA promoter / enhancer control baseline, but also retains high tissue -specificity. To test the efficacy of our prostate tissue -specific promoter / enhancer, we chose the most active variant of Herpes Simplex Virus -Thymidine Kinase ( HSV-TK.sr39 ) since this suicide gene therapy can also be used for non -invasive imaging of gene expression by PET scanning. The expression levels and the distribution of HSV-TK.sr39 gene driven by CMV promoter were followed in our CL1 -GFP tumor model using PET imaging. This imaging system will be used to evaluate the in vivo activity and specificity of the improved PSA promoter / enhancer in the LAPC4 tumor model. We are also investigating the efficacy and therapeutic value of Apo2L / TRAIL, a TNF family member with more selective cytotoxicity against tumor cells, for the treatment of prostate cancer. Our goal is to target selectively prostate tumor cells with TRAIL gene expression driven by improved PSA promoter / enhancer. We have already generated adenoviral vectors containing Apo2L / TRAIL driven by control CMV promoter and by improved PSA promoter / enhancer. We are presently evaluating the pro -apoptotic activity of the TRAIL gene therapy and its advantage in comparison to the use of soluble TRAIL protein. Our ongoing in vitro and in vivo studies will demonstrate the feasibility of the TRAIL gene therapy to target and eradicate prostate cancer cells.
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Non -invasive imaging of prostate-specific gene transfer in advanced human prostate cancer xenograft models Gene therapy represents a potential alternative or adjuvant to existing strategies in the treatment of advanced, androgen -independent ( AI ) prostate cancer. Non -invasive imaging modalities and transcriptional targeting have emerged as two tools to facilitate the rational design and improve upon the safety of vector -based cancer gene therapy. Our prostate -targeting vector ( AdPSE -BC -luc ) is a recombinant adenovirus ( Ad ) with a luciferase gene driven by an enhanced prostate -specific promoter derived from PSA regulatory region. In the present study, we used the noninvasive and highly sensitive optical charged coupled device ( CCD ) imaging to investigate the location, magnitude, and kinetics of luciferase expression in xenograft models of both androgen -dependent ( AD ) and androgen -independent ( AI ) prostate cancer. AdPSE -BC -luc was able to strictly exclude expression in non -prostate tissue such as liver. AdPSE -BC -luc displayed greater than 200,000 -fold lower activity compared to constitutive AdCMV-luc after systemic tail -vein vector injection as measured by both CCD imaging and luminometry. On the other hand, by intra -tumoral administration AdPSE -BC -luc was able to mediate robust luciferase signal in AD ( LAPC -4 and LAPC -9 ) and AI LAPC -4 human prostate cancer xenografts. In fact, the level of luciferase expression in AI LAPC -4 tumors was 7 -fold higher than in the AD parental LAPC -4 tumors. The elevated luciferase expression pattern paralleled the respective endogenous PSA expression pattern. The non -invasive nature of CCD imaging allowed us to follow the luciferase expression sequentially in time in the same animals. As we followed AdPSE -BC -luc mediated luciferase expression in LAPC -4 tumor -bearing mice over a period of three weeks, transduction of distant metastases to the lung and para -vertebral musculature were visualized. Follow -up analyses of these lesions by histology, immunohistochemisty, and RT-PCR confirmed they were human neoplastic lesions that expressed PSA. These results attest to the power of a sensitive, non -invasive imaging modality and the specificity of our prostate -targeting vector. Combining these two refinements could greatly enhance the safety and monitoring of prostate cancer gene therapy such that therapeutic and cytotoxic schemes can be designed and tested for the most advanced metastatic and AI stage of disease.
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Connexin 26 as a target of gene therapy Human bladder cancer cell lines UM -UC -3, UM -UC -6, UM -UC -14, and T24, human prostate cancer cell lines PC -3 and DU -145, human colon cancer cell lines LoVo and CaCo -2, and human renal cancer cell lines UC -RC -2 and UC -RC -6 were infected with Ad -Cx26 or a control adenovirus ( Ad -CTR ). Ad -Cx26 infection in vitro resulted in greatly decreased growth ( 66.3 -78.5% inhibition at 7 days ) and colony formation in soft agar ( > 99% inhibition at 21 days ) compared to cells infected with Ad -CTR in all of bladder cancer cell lines. We also observed growth inhibition in prostate, colon, and renal cancer cell lines treated with Ad -Cx26. Increased apoptosis was noted in all of bladder cancer cell lines infected with AdCx26 as determined by FACS using the Apo -BrdU kit. In contrast, an immortalized normal human bladder cell line, SV-HUC, infected with AdCx26 exhibited minimally decreased cell growth ( 3.8% inhibition at 7 days ) and no significant apoptosis compared to infection with Ad -CTR.
In vitro infection of UM -UC -3 and UM -UC -14 cells with Ad -Cx26 produced complete suppression of tumor formation in nude mice. These cells infected with Ad -Cx26 ex vivo exhibited morphological changes associated with apoptosis and demonstrated increased TUNEL staining in vivo. Apoptosis was not seen in Ad -CTR infected tumors. To further assess the effects of Cx26 in vivo, we treated established UM -UC -3 and UM -UC -14 tumors by direct injection of Ad -Cx26 or Ad -CTR. Treatment with AdCx26 resulted in significant tumor suppression for more than 30 days after treatment compared with Ad -CTR treatment and induced apoptosis as demonstrated by TUNEL assay. Ad -CTR did not cause apoptosis. Repeated injections of Ad -Cx26 prolonged the duration of tumor suppression. Delayed resumption of tumor growth was associated with loss of Cx26 expression.
We explored combination therapy with Ad -Cx26 and cisplatin to improve the efficacy of gene therapy. In vitro infection of Ad -Cx26 in UM -UC -3, UM -UC -6, and UM -UC -14 cells significantly increased the cytotoxicity of CDDP compared with mock or control infection. Established UM -UC -3 and UM -UC -14 tumors were treated with three injections of Ad -Cx26 and two intraperitoneal administrations of 5 mg / kg CDDP on days 9 and 15. Combination therapy with Ad -Cx26 and cisplatin resulted in significant suppression of tumor growth compared to various control groups. This treatment resulted in 5 out of 10 mice with UM -UC -3 tumors and 4 out of 10 mice with UM -UC -14 tumors to be tumor -free for more than 120 days.
These data demonstrate that Cx26 can potentially be used for gene therapy not only in bladder cancer but also in other types of cancers. 1 Sidney Kimmel Cancer Center, San Diego, CA 92121; and 2 Cancer Center, University of California at San Diego, La Jolla, CA 92093. The activating transcription factor 2 ( ATF -2 ) is a member of the ATF / cAMP -response element -binding ( CREB ) protein family of basicleucine zipper proteins involved in cellular stress response. ATF -2 target genes which include TNF, TGF, cyclin A and c -jun, have been implicated in neoplastic transformation. However, the role of ATF -2 in this process remains to be elucidated. Analogous to one of its dimerization partners, c -jun, ATF -2 undergoes amino terminal phosphorylation by Jun N -terminal kinase ( JNK ). This modification has been shown to regulate ATF -2 protein stability and ubiquitination. Amino terminal phosphorylation of cjun leads to enhanced transactivation activity and may play a role in mediating apoptosis induced by stress responses and repair following treatment with DNA damaging agents used as chemotherapeutic drugs. Furthermore, evidence suggests phosphorylation has an important function in cellular transformation in a variety of settings. To investigate the possibility that amino terminal phosphorylation of ATF -2 can exhibit a similar effect, we have used a breast cancer model to study the effects of both ATF -2 overexpression and amino terminal phosphorylation of ATF -2. The breast cancer cell line BT474 that overexpresses the ErbB2 receptor, a molecule upregulated in almost 40% of human breast cancers, was transfected with wild -type ATF -2 or a phosphorylation -deficient mutant of ATF -2 with amino acid substitutions at Thr -69 and Thr -71 to alanine. Stable clones were generated and selected clones were analyzed for their sensitivity to cytotoxic drugs, including cisplatin, a DNA -damaging agent. Clones overexpressing ATF -2 exhibited increased resistance to cisplatin while those expressing mutant ATF -2 showed increased sensitivity. Moreover, mutant ATF -2 expressing clones also demonstrated decreased growth rates.
O-63
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Herceptin augments Ad -mda7 mediated killing in Her-2 over-expressing breast cancer cells An estimated 185,000 new cases of breast cancer were reported in 2000 with almost 42,000 deaths. It is known that breast cancers over -expressing the Her -2 / neu oncogene are more resistant to standard therapies and these patients have a poor prognosis. Recombinant humanized anti -Her -2 antibody ( Herceptin 1 , Trastuzumab ) has been shown to specifically inhibit the growth of breast cancer cells over -expressing the Her -2 / neu receptor, and has demonstrated activity alone and as an adjuvant therapy in clinical trials against Her -2 / neu -overexpressing breast cancer. The specific anticancer activity of Ad -mda7 has been demonstrated in vitro and in vivo, and its role in inducing selective and rapid apoptosis of cancer cells has been well documented.
In this study, the novel combination of Herceptin and Ad -mda7 was evaluated against a series of breast cancer cell lines. The combination showed supra -additive activity in rapidly inducing cell cycle arrest and apoptotic death of Her -2 / neu overexpressing breast cancer cells ( MDA -MB -453 and SKBr3 ). T47D and MCF -7 were evaluated as prototypic Her -2 negative cell lines; neither cell line showed cytotoxicity enhancement by addition of Herceptin. A potential mechanism responsible for the activity of the combination of Herceptin and Ad -mda7 was the ability to sequester betacatenin to the plasma -membrane via regulation of E -cadherin. This sequestration would cause inhibition of beta -catenin induced transcriptional activation and cell proliferation. This novel strategy combining Ad -mda7 and Herceptin may also be used against other Her -2 overexpressing cancer lines. NewLink Genetics Corporation, Ames, IA. The sodium iodide symporter ( NIS ) is a transmembrane protein that is present in thyroid cells and transports inorganic iodide from the plasma into the cell cytoplasm. We have designed a novel approach to cancer gene therapy that exploits this unique property of NIS. In our work, we used a replication defective adenovirus for delivery of the rat NIS gene into human prostate cancer cells ( DU 145 ), in both in vitro assays, and in vivo animal model. The NIS gene was cloned into an adenoviral shuttle vector, and a recombinant adenovirus ( Ad -rNIS ) was generated using homologous recombination. Recombinant adenoviral clones were screened by PCR and assayed for intracellular 125 I uptake in DU 145 cells, in order to select the most functionally active virus. In vitro the degree of 125 I uptake was vastly superior using the rat NIS gene compared to the human NIS gene expressed after transduction with 50 MOI of an adenoviral vector. Western blot analysis confirmed high level protein expression of the rat NIS gene after in vitro transduction. We designed a tumor model using nude mice to measure the in vivo efficiency in DU 145 cells infected in vivo with Ad -rNIS. Nude mice were implanted subcutaneously in their flank with 2Â10 7 DU 145 cells. Following tumor growth, we injected 10 8 pfu of Ad -rNIS intratumorally a total of three times over a 72 -hour period. Control mice received: a ) injection of Ad -rNIS and no 131 I; b ) injection of 131 I only; c ) injection of Ad -TK ( adenovirus containing HSV thymidine kinase gene ) and 131 I. Twenty -four hours following the last injection of adenovirus, 1 mCi of 131 I was injected intraperitoneally. In all three control groups tumors continued to grow. In the experimental group ( Ad -rNIS and 131 I ), tumors grew much more slowly during observation. These data suggest that a new approach using the rat sodium iodide symporter with radioactive iodide administration can be used successfully for in vivo cancer gene therapy.
O-66
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Radiation enhances vaccinia -p53 -mediated therapy in a glioma model In our previous experiments we demonstrated that recombinant vaccinia virus expressing human p53 enhanced ionizing radiation efficacy against highly aggressive, radio -resistant p53 -deficient C6 rat glioma. The purpose of this study is to evaluate vaccinia -p53 -mediated ( VV-TK -53 ) antitumor effects in combination with radiation in murine subcutaneous and intracranial glioma models. Single and multiple gamma -radiation treatments ( 60 Co, 4 Gy ) were applied to established C6 glioma tumors in athymic mice and the virus treatment was performed 16 -18 hours thereafter. PBS, L -15 control and VV-TK -53 viruses were tested by intratumoral injection ( 2Â10 6 PFU / 50 l ). Combination of VV-TK -53 and radiation in both single and multiple therapies resulted in significant ( P < 0.05 ) tumor growth inhibition in mice on day 30 compared to single modalities. Immunohistochemical analysis of tumor sections demonstrated significant p53 protein expression over 20 days after VV-TK -53 treatment. Analysis of mouse blood and spleen cells with multiple combination treatments showed significant increases in certain leukocyte populations. PanNK + , CD25 + and B220 + cells were significantly elevated, preferentially in the spleen, after multiple combination treatments. In our preliminary experiment on combined proton radiation and vaccinia -p53 therapy, we found that magnetic resonance imaging ( MRI ) is an effective tool for non -invasive monitoring of intracranial glioma growth progression in Lewis rats. Our results demonstrate that radiation significantly improves the efficacy of vaccinia virus -mediated tumor suppressor p53 therapy, and suggest that this combined treatment may be a promising strategy for glioma therapy.
The view, opinion, and / or findings contained in this report are those of the author( s ) and should not be construed as a position, policy, decision or endorsement of the federal government or the National Medical Technology Testbed, Inc. This study was supported in part by the National Medical technology Testbed, Inc. affect of androgen ablation and of many chemotherapeutic agents. In an attempt to develop new effective therapeutic strategies to defeat androgenindependent prostate cancer, we have hypothesized that the delivery of apoptotic genes in prostate cancer cell lines results in apoptosis, and that overexpression of these genes can be directed to prostatic epithelium by using prostate -specific promoters. In initial work we used a binary system of adenoviruses overexpressing Bax ( consisting of a GAL4 / VP16 fusion protein [ construct Ad -GV16 ] under the constitutively active PGK promoter that functions as transactivator of a Bax cDNA driven by the GAL4 / TATA promoter [ construct AdGT-Bax ] ). This binary system effectively overexpressed BAX and induced apoptosis by activating the mitochondrial pathway within 24 hours post -infection in five prostate cancer cell lines ( LNCaP, LNCaP -Bcl -2, PC -3, TSUPr( 1 ) and DU -145 ). In addition, three injections of the Bax overexpression system into PC -3 cell tumors in nude mice in vivo caused a 25% regression in tumor size corresponding to a 90% reduction relative to continued tumor growth in animals injected with the control binary system expressing Lac -Z. More recently, the Bax cDNA was placed under the control of the modified probasin promoter ( ARR 2 Pb ) in an adenoviral construct ( AvARR 2 Pb -Bax ). Infection studies with this construct have shown that BAX is selectively overexpressed in androgen receptor positive ( AR + ) prostate cancer cell lines while under the control of this promoter. This overexpression significantly exceeded that obtained using the constitutively active binary system, and was followed by apoptosis following activation of the mitochondrial pathway. This applied also to AR + but androgen insensitive cell lines such as the C4 -2. Experiments performed using LNCaP cells in nude mice support the concept that this approach works also in vivo in non -castrated animals. Additional experiments using the combination AvARR 2 Pb -Bax and AvARR 2 Pb -Bad will be presented. In conclusion, manipulation of the apoptotic pathway using adenoviral -mediated overexpression of Bax ( and Bad ) is an effective way to kill prostate cancer cell lines. Use of the modified probasin promoter ARR 2 Pb is a reliable way to overexpress Bax ( and Bad ) selectively in AR + prostatic epithelium.
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Tumor specific adenovirus in combination with conventional therapies produces anti -tumor synergy without increasing toxicity Nagarajan Ramesh, Yuanhao Li, Pinky Amin, Jeanette Dilley, and De -chao Yu Cell Genesys, Inc., 342 Lakeside Drive, Foster City, CA 94404. Replication competent viruses are being investigated as potential anticancer agents. The utilization of the replication competent cytolytic adenovirus as a therapeutic modality shows much promise. Applying the attenuated replication competent adenovirus ( ARCA ) technology we have demonstrated antitumor efficacy employing adenovirus variants CV706, and CV787 specific for prostate cell, CV890 specific for liver cell and CV884 specific for bladder tumors, in established tumors in nude mouse xenografts. In order to increase the antitumor efficacy with lowered systemic toxicity, combination studies with conventional modes of treatment were investigated. Both in vitro and in vivo studies have shown significant synergistic effects of ARCA in combination with radiation or chemotherapy. LNCaP xenografts, a prostate tumor cell line, when treated with CV706 ( 1Â10 7 particles / mm 3 of tumor ) and 10 Gy of single fraction local tumor radiation resulted in > 95% of tumor volume reduction in 6 weeks which was 6.7 -fold greater than the predicted additive effect. In addition we observed significant reduction in the number of blood vessels in the tumors treated with CV706 in combination with radiation. A 50 -fold reduction in the levels of CV706 was required to eliminate preexisting tumors in the combination treatment compared with a single agent treatment. CV787, another PSA + prostates cell specific ARCA variant, showed significant synergy in antitumor efficacy when combined with chemotherapeutic agents such as Paclitaxel and Docetaxel. A synergistic increase in cytotoxicity towards LNCaP resulted when combined with taxane. In combination with docetaxel ( 12.5 mg / kg ), a single injection of 1Â10 8 particles of CV787 led to a complete elimination of xenograft tumors in nude mice within 4 weeks. This corresponded to a 1000 -fold increase in the therapeutic window compared to CV787 monotherapy. Immunohistochemical analysis of treated tumors suggested that both virus replication dependent cytolysis and apoptosis contributed to the antitumor effect of CV787 and taxane. The synergistic antitumor efficacy was also observed with a hepatocellular carcinoma specific ARCA variant CV890 or a bladder cancer specific ARCA variant CV884 when combined with chemotherapeutic agents. Additionally, we also observed no reduction in the replication or specificity of all the viruses in the presence of synergistic agent and no increase in toxicity after combined treatment. The Drosophila melanogaster multisubstrate deoxyribonucleoside kinase ( Dm -dNK ) has a broad substrate specificity and a very high catalytic rate for phosphorylation of nucleosides and nucleoside analogs. We have recently shown that overexpression of Dm -dNK in cancer cell lines increases the cells' sensitivity to several cytotoxic nucleoside analogs and the enzyme may accordingly be used as a suicide gene in combined gene / chemotherapy of cancer. In the present study we further characterized the enzyme for possible use as a suicide gene. We constructed a replication deficient retroviral vector that expressed either the wild -type enzyme that localizes to the cell nucleus or a mutant ( arg247ser ) that localizes to the cytosol. A thymidine kinase deficient osteosarcoma cell line was transduced with the recombinant virus and we compared the sensitivity and bystander cell killing when the cell lines were incubated with the pyrimide nucleoside analogs ( E ) -5 -( 2 -bromovinyl ) -2 0 -deoxyuridine or 1 --D -arabinofuranosylthymine. In summary, we showed that the cells' sensitivity and the efficiency of bystander cell killing was not dependent on whether Dm -dNK was located in the nucleus or cytosol.
Hematopoietic Gene Transfer O-71
In vivo selection of murine and human chemoresistant primitive hematopoietic cells after retrovirus transfer of mutant O 6 methylguanine DNA methyltransferase (MGMT) diseases. Since the dose -intensification of many cancer chemotherapy protocols is limited by hematopoietic toxicities, generation of primitive hematopoietic cells resistant to DNA damage may protect patients from blood cytopenias caused by alkylating agents. In addition, some drugresistance gene / chemotherapy combinations may be useful in selecting and thereby amplifying transduced cells populations in vivo, an application that could be useful in the treatment of genetic blood diseases in which expression of the gene of interest does not lead to a selective proliferative advantage. Our laboratory has previously demonstrated that the combination of over -expression of the P140K mutant of MGMT and treatment in vivo with 6 -benzylguanine ( 6 -BG, a pharmacologic inhibitor of MGMT ) and 1,3 -bis ( 2 -chloroethyl ) -1 -nitrosourea ( BCNU ) in mice not only leads to markedly enhanced protection from blood toxicities of these drugs, but also leads to highly effective selection of transduced hematopoietic stem cells 
O-72
Gene transfer using SV40 vectors packaged in vitro Plasmid DNA packaged in vitro using recombinant SV40 capsid proteins produced in insect cells is a very efficient gene delivery system for many cell types. The data indicate that plasmid DNAs up to 15 kb in size can be packaged in vitro into SV40 capsids and delivered efficiently into cultured human hematopoietic cells, with no requirement for SV40 sequences in the packaged DNA. The human multidrug resistance gene ( MDR1 ) or the GFP reporter gene was delivered into human erythroleukemia K562 cells, or human lymphoblastoid 0.45 cells. The expression of human P -glycoprotein ( P -gp ), the MDR1 gene multidrug efflux pump, was determined by measuring cell surface expression using a human -specific monoclonal antibody to P -gp ( MRK -16 ) or a functional assay in which rhodamine -123 efflux is measured in the absence or presence of specific P -gp inhibitors. Transduction was more efficient in 0.45 cells that are rich in MHC class I receptors, a cellular recognition target of SV40. The SV40 early promoter was compared to the CMV promoter. Although CMV was slightly stronger in most cells, both reporter genes expressed better with an intron than without. Plasmids carrying the reporter genes under SV40 or CMV promoters expressed only for three weeks unless cells were selected with cytotoxic drugs for P -gp expression. Long -term expression over three months was achieved only when using plasmids that carry LTRs, or with drug -selected transductants. A variety of vectors encoding the MDR1 gene, up to 15 kb in size, with or without SV40 sequences were packaged in vitro. These experiments demonstrate that in vitro packaging with SV40 capsid proteins does not require any SV40 sequences including the ori sequence. When an 8.1 kb plasmid was packaged using either VP1 only ( the major capsid protein constituting the outer shell of SV40 ), or a mixture of the three capsid proteins ( VP1, VP2, and VP3 ), and a fourth late protein ( agno, which is not present in the mature virion ) the same level of P -gp expression was obtained. However, when vectors 9.5 kb and larger were packaged using all proteins, P -gp expression was decreased compared to packaging with VP1 alone. Virions packaged in vitro looked similar to wild -type SV40 when examined by electron microscopy whether VP1 alone or all capsid proteins were used. We conclude that in vitro packaging permits transduction of at least 15 kb of plasmid DNA without the requirement for any viral sequences. Thus, this SV40 in vitro packaging system should be useful for efficient introduction of DNA sequences into hematopoietic cells such as would be necessary to introduce the MDR1 gene into such cells to protect bone marrow from the cytotoxic effects of chemotherapy.
O-73
Optimization of hematopoietic stem cell gene transfer methods using the non -human primate competitive repopulation model: recent progress toward clinical application Although encouraging results in murine hosts were reported over two decades ago, the successful widespread clinical application of hematopoietic stem cell based gene transfer methods using integrating vectors has been hampered predominantly by the low level of genetically modified cells attainable in large animals and humans to date. A number of approaches aimed at increasing the chances of vector and target cell interaction such as pseudotyping of vector particles with alternative envelope proteins, colocalization of vector and target cells on recombinant human fibronectin fragments and the inclusion of various primitively acting hematopoietic growth factors during transduction have been proposed based on both in vitro and murine in vivo data. To develop high efficiency, clinically feasible transduction methods appropriate for human clinical trials, we have utilized the rhesus macaque competitive repopulation model, exploiting the similarities between rhesus and human cytokine influences, stem cell cycling kinetics, hematopoietic demand and retrovirus cell surface receptor distribution. In this model, we have recently obtained clinically relevant levels of genetically modified circulating progeny at 10% or higher over a prolonged follow -up period post -transplantation through extensive studies comparing various transduction methods. Retroviral integration site analysis reveals that the contribution to hematopoiesis by genetically modified cells is polyclonal with common integration sites among different hematopoietic lineages suggesting successful transduction of truly pluripotent hematopoietic progenitors. The stable, high level in vivo gene marking derived from multiple transduced clones attainable in our non -human primate model is encouraging for application of hematopoietic stem cell based gene transfer in humans, and the first such success has been recently reported in humans in children with SCID renewing enthusiasm for clinical trials in disorders where modest, non -regulated expression will suffice. Recent efforts to deliver therapeutic genes such as human beta -globin in which more complex regulation is required are now underway. Finally, hematopoietic stem cell plasticity may allow their application the treatment of a wide variety of disorders affecting cells or organs outside of the hematopoietic system. Fanconi Anaemia is a rare genomic instability inherited syndrome. The unique treatment for life -threatening early aplastic anaemia is alloBMT associated to acute toxicity and secondary tumours. Gene therapy of BM -failure is an attractive alternative. Obstacles account for difficulties encountered so far: ( i ) the scarcity of haematopoietic progenitors; ( ii ) their flimsiness which does not allow in vitro growth for longer than a week; ( iii ) gene transfer technical limitations. These last two issues have been investigated in this study; focusing on FA -A patients ( 70% ). Functional correction was first demonstrated on patient's EBV-and primary mesenchymal -cells. 30 experiments were performed on unfractionated BM samples from nine patients ( 8 A, one C ). This is using FOCHA -FICD retrovirus -and cPPT-SIN lenti -vectors: pRRLSIN -18 / WPRE ( Luigi Naldini ) and our original pLENP29SIN. Prestimulation conditions were thoroughly defined using low GFs concentrations except for TPO, in SCGM medium. Growing primary haematopoietic cells in hypoxia and N -acetyl -cystein resulted in a dramatic improvement of cell -counts and clonogenic assays. The colorectal carcinoma ( CRC ) antigen ( Ag ) GA733 ( EpCAM ) has proven to be a useful target in passive immunotherapy with monoclonal antibody and in active immunotherapy with anti -idiotypic antibodies or recombinant protein in cancer patients. In these trials single epitopes or extracellular domain of the Ag were targeted. We postulated that targeting the full -length Ag by viral vector immunization may be more efficacious than targeting a fraction of the Ag by protein immunization. Therefore, the GA733 Ag was expressed in adenovirus ( Ad ), and vaccinia virus ( VV ). Recombinant VV and Ad protected mice against a challenge with GA733 Ag -positive syngeneic CRC cells. Recombinant VV and Ad induced Ag -specific cytotoxic antibodies, and proliferative and delayedtype hypersensitive lymphocytes. However, only the Ad recombinant induced Ag -specific cytolytic T lymphocytes and regression of established tumors. Importantly, cured mice were protected against challenge with Ag negative tumors. Both the human GA733 Ag and the murine homologue mEGP are homotypic adhesion proteins. Ad -mEGP, only when combined with IL -2, significantly inhibited growth of established mEGP -positive tumors. This is in contrast to the Ad vaccine expressing the human Ag which was effective without IL -2. Recombinant Ad expressing the human CRC Ag GA733 and combined with IL -2 is a candidate vaccine for CRC patients. The need for IL -2 to induce protective immunity to self Ag with viral vector was confirmed in a transgenic mouse model of melanoma targeting CD63. ( Supported by NIH grants CA60595, CA25874, and CA74294 ). Since 1993 we have been involved in clinical trials of late stage cancer patients ( mainly melanoma ) with various gene therapy agents, mostly based on retroviral vectors. These include cellular therapies prepared ex vivo and direct injection of tumor lesions with the vectors. The genes were gamma interferon and thymidine kinase in conjunction with ganciclovir. Initial trials used autologous tumor transduced ex vivo with gamma Interferon, irradiated and readministered. Although promising immunological and clinical response data were observed, the overwhelming logistics of the trials ( about 230 patient biopsies to complete treatment on 18 patients ) made the approach impractical. Preclinical mouse data with both TK and interferon vectors directly injected into tumors showed transduction of up to 25% of cells in a specific mouse tumor nodule, and antitumor effects in treated mice with both genes. In the interferon treated mice strong evidence of systemic effects were seen in a CT26 metastatic model. An initial trial with intralesional injection of interferon vector in 13 subjects showed that in some lesions 5% to 8% of biopsied cells were transduced. A trial of 16 patients with TK in conjunction with ganciclovir failed to show any clinical benefit protein. In vitro studies have demonstrated that Ad -mda7 induces apoptosis specifically in tumor cells and causes secretion of a soluble form of MDA -7 protein. We have recently shown that the MDA -7 protein has structural similarity with the IL -10 family of cytokines, and mda -7 appears to be a novel member of this family. Unlike the prototypic Th2 cytokine IL -10, MDA -7 appears to be a novel Th1 cytokine and has recently been termed IL -24.
O-74
We have evaluated immune cell phenotypic changes and cytokine modulation in patients treated intra -tumorally with INGN 241 in an ongoing Phase I single dose, dose escalating clinical trial. INGN 241 was administered intra -tumorally at doses ranging from 2Â10e10 to 2Â10e12 vp to patients with surgically resectable advanced carcinoma, and tumors were resected 24 hours post -injection. Transient increases in the systemic levels of IL -6 ( 6 of eight patients tested ); IL -10 ( 6 of 8 ); gamma -IFN ( 3 of 3 ); GM -CSF ( 2 of 3 ), and TNF -a ( 2 of 3 ) were observed after INGN 241 treatment. The cytokine levels increased within 24 hours after vector administration and tended to normalize to baseline levels after 3 -7 days. These findings are similar to prior observations of elevated serum cytokines in patients who received intravenous adenovirus ( Nemunaitis et al, 2001 ) , and suggest the activation of innate and adaptive immune responses. Immunophenotype analyses indicated minor fluctuations in leukocyte subsets after treatment. A trend of increased CD8 + T-cells at levels up to 60% of total mononuclear cells was observed in the majority of patients. If MDA -7 / IL -24 is in fact functioning as a Th1 cytokine, this may explain the enhanced CD8 + cell levels. We anticipate that INGN 241 will both induce apoptosis in treated tumors ( as already observed, even at low doses of vector ) and also stimulate the immune system to enhance antigen presentation and activate the cellular immune response against tumor cells. We believe the combination of tumor -selective apoptosis induction and immune stimulation will enhance anti -tumor effects of this novel gene therapeutic.
O-82
Immunotherapy using activated dendritic cells transduced with full -length wild -type p53 Accumulation of p53 protein in tumor cells as a result of mutations in the p53 gene occurs in more than 50% of human tumors. p53 -derived epitopes are expressed on the surface of tumor cells and can serve as targets recognized by cytotoxic T lymphocytes ( CTL ). This makes p53 -based immunization an attractive approach to cancer immunotherapy. We have previously shown that murine DCs transduced with Ad -p53 ( encoding human wild type p53 ) elicited potent CTL responses against target cells expressing different mutant p53 genes, including those from different species, and this response was sufficient for tumor protection. However, it had not been established whether an immune response against the p53 selfprotein could be generated in vivo. Dendritic cells ( DCs ) generated from mouse bone marrow progenitors were transduced with adenoviral construct containing murine full -length wild -type p53 ( Ad -mp53 ). Repeated immunizations with these cells protected 60% of mice against challenge with MethA sarcoma cells bearing point mutations in p53 gene. Activation of DCs via ligation of CD40 significantly improved the results of immunization: all mice were protected against MethA sarcoma. The treatment of MethA tumor -bearing mice with activated Ad -mp53 -transduced DCs showed complete tumor rejection in four out of six mice with considerable delay of tumor growth in the remaining animals. The specificity of antitumor immune response was confirmed by CTL assay. The analysis of phenotype and function of DCs demonstrated that the effect of CD40 ligation on these cells was enhanced by their infection with Ad -mp53. The level of neutralizing anti -adenovirus antibody was moderately elevated in these mice. Importantly, no signs of autoimmune reaction were evident during detailed pathological evaluation of treated mice. These data demonstrate that activation of DCs dramatically increases the efficiency of anti -p53 immunization. This approach may be applied in the immunotherapy of cancer.
O-83
Generation of antigen -specific cells by T-cell receptor gene transfer The adoptive transfer of tumor -specific T cells expanded in vitro has shown significant therapeutic value against some cancers. This strategy is limited though, as it is often difficult and costly to obtain T cells of clinical value. The transfer of T-cell receptor ( TCR ) genes to generate tumorspecificity in T cells provides a mechanism to overcome these limitations. To evaluate the feasibility of such an approach, we are developing a murine TCR -gene -transfer model utilizing the genes encoding the OT-1 TCR. This TCR recognizes an epitope present in a model tumor antigen, ovalbumin, expressed in the murine thyoma, E.G7 -OVA. To begin this project, both subunit genes encoding this TCR were placed in a replication -deficient retroviral vector. After transducing murine T cells and utilizing the drug resistance gene, neomycin, present in the viral vector, we were able to culture and expand large numbers of drug resistant T cells. Over half of these T cells expressed high levels of both retrovirally encoded TCR subunits. Importantly, this demonstrates the ability of our vector to direct simultaneous expression of three genes ( TCR alpha, TCR beta, and neomycin genes ). Furthermore, when analyzed for in vitro functional ability, these T cells were able to recognize E.G7 -OVA tumor cells, as assayed for both via cytotoxicity and cytokine release. These results show for the first time that murine T cell can be endowed with tumor -specificity via transfer of TCR genes. Encouraged by these results, we are now evaluating the therapeutic efficacy of these retrovirally modified T cells in a murine tumor model. This may ultimately serve as a new avenue in cancer treatment.
O-84
Immunotherapy through TCR gene transfer The antigen -specificity of T lymphocytes is solely dictated by the T-cell receptor ( TCR ) and chains. Consequently, genetic transfer of TCR chains may form an appealing strategy to impose a desirable tumor -antigen specificity onto cytotoxic or helper T-cell populations. We here describe the genetic introduction of a T-cell receptor into peripheral T cells in a mouse model system. These experiments reveal that T cells redirected by TCR gene transfer expand dramatically upon in vivo antigen encounter and efficiently home to effector sites. In this setting, TCR gene transfer is not associated with any significant autoimmune pathology. Furthermore, very small numbers of TCR -transduced T cells can promote the rejection of antigenexpressing tumors in vivo ( Nature Immunology, 2001, in press ). These data suggest the redirection of T cells by TCR gene therapy as viable new strategy for the rapid induction of tumor -specific immunity. This technology may be particularly useful in settings where the capacity of the natural T-cell repertoire is compromised due to immune deficiency, or in cases where the tumor antigen is a self antigen, for which the endogenous T-cell repertoire is limited in size and activity.
O-85
Murine hepatoma hepa1 -6 cells expressing the membrane form of macrophage colony stimulating factor ( Mm -Csf ) are killed by macrophages in vitro and lead to tumor rejection and immunization against the parental tumor in vivo Qinghong Dan, H. Terry Wepsic, Kanga Morgan, Ramon Sanchez, Timothy R. Morgan, and Martin R. Jadus Veterans Affairs Medical Center Long Beach, CA and University of California, Irvine. Non -immunogenic mouse Hepa1 -6 hepatoma cells retrovirally transfected with the gene for the membrane isoform of macrophage colony stimulating factor ( mM -CSF ) but not for the secreted form of M -CSF ( sM -CSF ) were directly killed by murine bone marrow -derived macrophages in 24 -hour cytotoxicity assays. Macrophage -mediated killing of the mM -CSF -transfected cells was blocked by using excess recombinant sM -CSF showing that this cytotoxicity was M -CSF specific. Chemical inhibitors of phagocytosis such as iodoacetate, cytochalasin B, and gadolinium chloride also prevented the macrophages from killing these mM -CSF transfected tumor cells. This last finding indicates that phagocytosis is the probable mechanism of transfected tumor cell killing. When the transfected tumor cells were injected subcutaneously into syngeneic H -2 b C57BL / 6 mice, the mM -CSF transfected tumor was rejected in seven out of eight mice and failed to form tumors, while the viral vector control tumor cells formed tumors in nine out of nine mice. Those tumors that formed were different in nature, the viral vector tumors were solid tumors, while those the tumor formed by the mM -CSF expressing cells was smaller and had a necrotic central region. Histologically, the mM -CSF expressing tumor was infiltrated by macrophage -like cells, while the viral vector was devoid of these cells. Mice that were injected with the mM -CSF transfected cells lead to the generation of cytotoxic T cells that could specifically lyse the parental unmodified Hepa1 -6 cells in a 6 -hour 51 Cr release assay. This cytotoxicity was blocked by anti -CD8 antibody. Once the mice rejected the mM -CSF transduced cells they had rechallenge resistance to the unmodified parental Hepa1 -6 cells but not against unrelated B16 tumors. This study indicates that mM -CSF suggests that mM -CSF could be a novel and useful way for treating various liver cancers.
PD -86
Development of a dendritic cell recombinant DNA vaccine targeting the P210 BCR -ABL fusion domain Virology, City of Hope National Medical Center, Duarte, CA 91010. Chronic myelogenous leukemia ( CML ) is characterized by a t( 9;22 ) translocation which results in the expression of chimeric BCR -ABL fusion oncoproteins that are necessary for oncogenesis, unique to the leukemic clones, and represent enticing targets for immunotherapy. Furthermore, of hematological malignancies, the protective role of host immune responses has been most convincingly demonstrated for CML. As a strategy to augment anti -CML immune responses, we developed a candidate DNA vaccine based on recombinant adeno -associated virus ( rAAV ) vectors which specifically targets the b3a2 splice variant of the P210 BCR -ABL fusion region. We first demonstrated that primary human dendritic cells ( DCs ), the most potent antigen presenting cells currently known, could be transduced with rAAV vectors. An 835 bp cDNA fragment containing the P210 BCR -ABL b3a2 variant fusion domain and flanking sequences was inserted into an rAAV vector under control of the RSV promoter, yielding pCWRF8. 293 cells transfected with pCWRF8 expressed an appropriate transcript, as well as the predicted 25 -KDa truncated protein. Using an institutionally approved protocol, PBMCs from healthy donors were primed and restimulated in vitro with autologous DCs transduced with vCWRF8 ( DC / F8 ), vCWRAP, an equivalent control vector encoding human placental alkaline phosphatase ( hu -PLAP )( DC / AP, negative control ), or pulsed with a 25 -amino acid peptide ( Pb3 ) corresponding to the p210 BCR -ABL fusion domain ( DC / b3, positive control ). No specific responses were generated using DC / AP, the negative transduction control. In contrast, BCR -ABL vector transduced DC were capable of priming autologous T cells to an equivalent extent to the positive control, BCR -ABL peptide pulsed DC. Proliferative responses were demonstrable in four donors with MHC alleles previously described in the literature as capable of responding to the BCR -ABL fusion domain, but not in two donors with divergent alleles. In addition, CTL clones were identified that specifically lysed BCR -ABL peptide pulsed autologous B -lymphoid cell lines, but not control cells pulsed with irrelevant peptides. To determine whether the CTL clones recognize endogenously expressed BCR -ABL P210 b3a2 , K562 cells, a leukemic cell line, were engineered to express a variety of HLA alleles. CTL clones specifically lysed K562 cells expressing identical HLA alleles, confirming that responses were endogenous tumor antigen specific and MHC restricted. Although both CD4 + and CD8 + CTL directed against BCR -ABL epitopes could be generated in this system, CD4 + clones were more readily identified, implying that the frequency of CD4 + T-cell precursor anti -BCR -ABL was higher. Thus, the construct developed herein may serve as an important candidate for gene -based immunotherapy of CML.
PD -87
Human U251 -MG glioma cells expressing the membrane form of macrophage colony stimulating factor ( mM -CSF ) are rejected in immunodeficient mice Yijun Chen, Martin R. Jadus, Cheri Lloyd, Ramon Sanchez, Christina Delgado, and H. Terry Wepsic Diagnostic and Molecular Medicine Health Care Group, Veterans Affairs Medical Center, Long Beach, CA 90822; and Pathology Department, University of California, Irvine, CA 92117. Our previous experiments showed that the mM -CSF transduced rat T9 ( T9 -C2 ) glioma cells would not form tumors within syngeneic rats and could elicit immunity against other rat gliomas. We now translate this finding into a human glioma model. Human U251 -MG glioma cells were transfected retrovirally with human mM -CSF. After selection and cloning, the MG -2F11 clone expressed the highest concentration of mM -CSF out of 25 clones tested. The MG2F11 cells, but not the MGviral vector ( MG -VV ) were killed by rat macrophages in a 48 -hour cytotoxicity assay. Three weeks after inoculation of three hundred thousand cells, seven out of eight nude mouse injected with MG virus vector cells subcutaneously developed tumors while none of the eight nude mouse inoculated with MG2F11 cells developed a tumor ( P < 0.01 ). Nude mice also successfully rejected three million MG2F11 cells. TUNEL staining showed that most of the subcutaneous inoculated MG2F11 cells died through apoptosis within 20 hours after inoculation. Immunohistology revealed the presence of numerous macrophages and neutrophils. The nude mice initially rejected the MG2F11 cells were rechallenged with three hundred thousand cells MG parental cells, these mice developed subcutaneous tumors, indicating that no inherent immunological memory exists. Using more severe immunodeficient NIH -Xid -Scid -Nu mice, which lack T cells, B cells and NK cells, seven out of eight mouse inoculated with three hundred thousand cells MG -VV cells developed a subcutaneous tumor, while none of the mice inoculated with MG -2F11 developed a tumor ( P < 0.01 ). The U251 -MG cells were HLA MHC class I typed to be HLA -A2 + , B18 + / Bw6 + , C5 + . Studies are now underway, reconstituting immunodeficient mice with HLA -A2 matched human peripheral blood mononuclear cells to determine whether a human anti -U251 immune response can occur within these mice. Combined with our previous data in the rat glioma model, we believe that a mM -CSF -based glioma tumor vaccine could induce immune responses within human glioma patients against their gliomas.
